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Abstract 
Backgound: Fabry disease is an X-linked disease affecting glycosphingolipid 
metabolism due to deficiency of the lysosomal enzyme Į-galactosidase. The natural 
course of the disease is related to progressive accumulation of globotriaocylceramide 
(GL3) in various cell types and causes premature death from stroke, renal failure or 
cardiac disease. Modern therapies in many common kidney diseases, as well as in a 
rapidly increasing number of rare diseases, include potentially toxic and expensive 
drug interventions. As a consequence, it becomes important to use accurate methods 
for investigation of kidney disease.  
Aims: The aims of this thesis were to evaluate early Fabry nephropathy by means of 
morphologic and exact functional methods in children and young adults and to 
validate the safety of kidney biopsies in general. 
Materials and methods: Renal biopsies from thirteen young patients with Fabry 
disease (mean age 17.3 ± 7.5, range 7-33 years) were examined before and after long-
term (5 years) enzyme replacement therapy (ERT). Comparisons of different 
formulas for estimation of GFR (eGFR) and measured GFR (mGFR) were performed 
in 42 children with Fabry disease (mean age 12.3  ± 3.6, range 2-17 years). Safety 
evaluation of kidney biopsies was done in 715 paediatric (mean age 12.0 ± 4.9, range 
0.04-17.9 years) and 8573 adult (mean age 50.6  ± 17.7, range 18.0-94.4) cases 
registered from 1988 to 2010 in The Norwegian Kidney Biopsy Registry. 
Results: The baseline biopsies of Fabry disease patients showed disease specific 
potentially progressive morphologic changes in glomerular, tubulointerstitial and 
vascular compartments. In the follow-up biopsies complete clearance of glomerular 
endothelial and mesangial GL3 deposits was found in all patients and linear 
regression analysis showed a significant correlation between podocyte GL3-clearance 
and cumulative agalsidase dose  (r=0.804, p=0.002). Simultaneous eGFR and mGFR 
analysis showed that the widely used original Schwartz formula overestimated mGFR 
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by an average of 50.6 ml/min/1.73 m2 in our cohort with normal mGFR. Nationwide 
renal biopsy registry data showed that major complications after kidney biopsy were 
rare both in children and adults (blood transfusion 0.9 % and surgery/angiographic 
embolization 0.2 %), the most important risk factors for major complications were 
lower GFR and smaller centre size.  
Conclusions and consequences: Long-term ERT clears glomerular endothelial and 
mesangial GL3 deposits across all dosing regimens of agalsidase.  The reduction of 
Fabry disease specific damage in podocytes is dose-dependent, suggesting that 
podocyte damage may be a promising biomarker in Fabry nephropathy.  Kidney 
biopsy is a low risk procedure and we recommend a baseline biopsy in the 
assessment of early renal damage in Fabry disease. A follow-up biopsy after 5 years 
ERT is valuable in the evaluation of progression and reversibility of kidney damage. 
Several GFR formulas show low accuracy in the normal GFR-range. The new 
abbreviated Schwartz formula (2009) has the better performance and is recommended 
in the routine follow-up of children with Fabry disease. Additional mGFR is 
recommended when exact measurements are needed; e.g. when ERT is initiated. 
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1. Introduction 
1.1. Fabry disease 
1.1.1. Definition and history 
Fabry disease is an X-linked lysosomal storage disease due to absent or deficient 
activity of alfa-galactosidase A resulting in progressive accumulation of the neutral 
glycosphingolipid globotriaocylceramid (GL3) in many cell types, including 
endothelial cells in glomeruli and capillaries, renal cells (podocytes, mesangial and 
tubular epithelial cells), cardiomyocytes and nerve cells (1). Renal biopsies in Fabry 
patients typically show GL3 deposits in various kidney cells developing from early 
age (2-5). Importantly, the disease is a multisystemic disorder, and the natural course 
of the classic phenotype leads to premature death from renal, cardiac or cerebral 
disease, usually at the age of 40-50 years (6, 7). The overall life expectancy is 
reduced by about 25 years for males and about 10 years for females (8). However, 
over the later years it has become increasingly clear that Fabry disease is a 
heterogenous disease, even within the same family, with a wide spectrum of 
manifestations in both genders including seemingly asymptomatic patients (9, 10). 
The disease was first described in 1898 by two independently working 
dermatologists, Johannes Fabry in Bonn and William Andersson in London, 
describing the classical angiokeratomas in the skin (11, 12). Christian de Duve first 
described the lysosome in the 1950s, and was later awarded the Nobel Prize in 
Physiology for this achievement, and proposed the concept of enzyme replacement 
therapy (ERT) for lysosomal storage diseases (13, 14).  In 1965, observations by 
electron microscopy of  “extremely overcrowded lysosomes” in perivascular cells, 
endothelial cells, fibrocytes and smooth muscle cells in skin biopsies were reported as 
likely of genetic origin, and lack of lysosomal enzymes were postulated (15). Brady 
et al. identified the deficiency of the agalsidase enzyme in 1967 (16).  
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The human alfa-galactosidase A gene (GLA), located on the X-chromosome (Xq22.1) 
was structurally described in the 1980s (17). About 500 disease-associated GLA 
mutations have been reported in The Human Gene Mutation Database (18, 19). 
However, it is increasingly recognized that not all the mutations are pathogenic (10).  
The mechanisms for this variability are largely unknown, but random X-inactivation 
may explain why some women are asymptomatic whereas others may have similar 
progressive disease phenotypes as hemizygous males (20-22).  
 
1.1.2. Incidence 
The incidence of the disease is ranging from 0.015 to 80 per 100 000, the highest 
numbers found by neonatal screening in Italy and in Taiwan (23-30). In the latter 
population the majority (86 %) had a mutation found in later-onset cardiac phenotype 
patients (29, 31). In Western Norway the prevalence is estimated to 1:17 000 (32).  
 
1.1.3. Symptoms and organ involvement 
Initial symptoms in Fabry disease are normally seen in the first decade of life, earlier 
in boys than girls (33). The first symptoms are usually acroparesthesias which are 
seen in more than half of classically affected boys and girls (burning pain in hands 
and feet), abdominal complaints (diarrhoea, pain, bloating), and hypohidrosis 
(reduced sweating) (33). With increasing age the gradual development of renal, 
cardiac and cerebrovascular disease is observed, and has been reported as early as in 
the teens (26, 34, 35). Hearing disturbances are common and sudden deafness may 
occur even in childhood (26, 36). Most patients have symptoms and progressive 
disease in multiple organ systems, and different disease severity scoring systems have 
been developed  to estimate the total disease burden in individual patients; e.g. Mainz 
severity score index (MSSI), Fabry disease severity scoring index (DS3) and the 
Fabry international prognostic index (FIPI) (37-39).  
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1.1.4. Enzyme replacement therapy 
Before the era of enzyme replacement therapy (ERT) in Fabry disease, the treatment 
was essentially symptomatic such as alleviating the neuropathic pain, treating cardiac 
and renal disease or palliative, like dialysis or renal transplantation, not interfering 
with the other multi-organ manifestations. Enzyme replacement therapy was for the 
first time described by Brady et al. in 1973 in two Fabry patients using 
ceramidtrihexosidase purified from human placental tissue (40). Alfa galactosidase A 
from spleen and plasma was a few years later given to two Fabry patients by Desnick 
et al (41). Two brands of recombinant alfagalactosidase preparations were developed; 
agalsidase alfa (Replagal£, TKT 5S, later Shire) from transfected human fibroblasts 
and agalsidase beta (Fabrazyme£, Genzyme) produced in a widely used hamster 
ovarian cell line. Early phase clinical trials performed in the late 1990s showed effect 
on tissue in humans: In patients treated with agalsidase alfa reduction of GL3 
deposits was shown in liver biopsy as well as in sheds of tubular epithelial cells in the 
urine sediment (42). Biopsies from Fabry disease patients treated with agalsidase beta 
showed dose-dependent clearance of GL3 in liver, kidney and endomyocardium (43). 
ERT was licenced in Europe in 2001 for the two different preparations, agalsidase 
alfa and agalsidase beta (44, 45). Both products are licensed for intravenous infusion 
every other week (eow), agalsidase alfa in the dosis 0.2 mg/kg/eow and agalsidase 
beta in the dosis 1.0 mg/kg/eow and both treatments may be given as home infusion 
(46). In the United States, only one preparation was licensed in line with their 
regulations for stimulating research on orphan diseases (44, 47). The Food and Drug 
Administration’s choice of agalsidase beta in 2003 as the licensed preparation was 
primarily due to evidence of short-term clearance of GL3 from glomerular 
endothelial and mesangial cells in phase III trials (44, 48). Studies on the effect of 
ERT on the kidney after six months of ERT (44) show clearance of GL3 in 
endothelium cells and mesangium cells with agalsidase beta 1.0 mg/kg/eow, and 
decrease of mesangial widening with agalsidase alfa 0.2 mg/kg/eow (45). Partial 
GL3-clearance of the podocytes (terminally differentiated cells with slow turnover 
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rates) has been shown in long-term (54 months) treatment with agalsidase beta 1.0 
mg/kg/eow (49). There are no published studies that include evaluation of renal 
biopsies after long-term treatment with agalsidase alfa 0.2 mg/kg/eow. Lubanda et al. 
performed a renal biopsy study in 21 adult male patients (median age 35.7 years, 
range 19.9-55.3 years) treated with agalsidase beta 1.0 mg/kg/eow for 6 months with 
subsequent dosereduction to 0.3 mg/kg/eow for another 18 months (50). They 
reported persisting complete clearance of GL3 deposits in the endothelium cells in 90 
% of the patients treated with reduced dose. The podocytes were not completely 
cleared in this short-term study, but partial clearance (scored as 0-3) was found in 3 
of 19 patients after 6 months of 1.0 mg/kg/eow and in 9 of 17 patients after another 
18 months of 0.3 mg/kg/eow compared to the baseline biopsy. Up to now, no clinical 
trials including renal biopsies in ERT-treated children have been published. 
 
1.1.5. Dosing of agalsidase alfa and agalsidase beta 
In vitro studies have shown similar effect of agalsidase alfa and agalsidase beta per 
mg substance (51, 52). After more than 10 years of ERT an important and still 
unresolved issue is the question of clinical equipotency of the two available enzymes 
(53, 54). No sufficiently powered randomized controlled trials have compared the 
efficacy of the two licensed drugs. A Dutch study was the first randomized controlled 
clinical trial comparing the two preparations of ERT, equal drug doses were tested, 
i.e.0.2 mg/kg/eow, and showed no difference between agalsidase alfa and beta after12 
months and 24 months in measurements of left ventricular mass (LVM) reduction or 
clinical adverse events (55). Comparison with the higher dose of agalsidase beta (1.0 
mg/kg/eow) showed a greater decline in urinary GL3 and reduction of LVM of the 
higher dose. Antibodies against alfagalactosidase A were frequent in male patients 
and may interfere negatively with the effect of ERT given at 0.2 mg/kg/eow, whereas 
infusion of 1.0 mg/kg/eow seemed more robust regarding neutralizing effects of 
antibodies (56). Interestingly, a recent study from the same group has demonstrated 
that antibodies induce a rise in plasma and urine lyso-GL3 (a promising surrogate 
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biomarker), a finding that may be associated with an increase in cardiac hypertrophy 
(57). Another study indicates that switch from agalsidase beta 1.0 mg/kg/eow to a 
lower agalsidase beta dose (0.5 mg/kg/eow) or agalsidase alfa 0.2 mg/kg/eow did not 
alter the clinical event rate over an observation period of about one year, although an 
increase in lyso-GL3 was observed. The clinical impact of these observations needs 
to be evaluated over a longer time-interval (58). There is also an on-going Canadian 
study comparing the clinical outcomes in patients randomized to either of the two 
drugs in their licensed doses (59). 
The majority of comparisons between  the two agalsidase preparations are indirect  
comparisons of clinical trials performed by the two pharmaceutical companies Shire 
and Genzyme as well as separate reports from the two observational databases Fabry 
Outcome Survey (FOS) (supported by Shire) and Fabry Registry (supported by 
Genzyme). Both drugs have numerous small reports demonstrating beneficial effects 
on stabilization or attenuation of progressive kidney disease and cardiac disease in 
patients with early organ affection, i.e. eGFR above 60 ml/min/1.73 m2 and 
proteinuria below 0.5 – 1.0 g/day. However, several small studies indicate that 
agalsidase beta 1.0 mg/kg/eow may be somewhat superior to agalsidase alfa 0.2 
mg/kg/eow (53, 54). Due to different analytical methods, inhomogenous patient 
groups, and insufficient sample sizes and outcome measures, it is not possible to draw 
any firm and evidence based conclusions as to the equipotency of the drugs. 
Moreover, the registry studies are hampered by serious selection bias (53).  All 
patients treated with ERT should be followed in a close and standardized way to 
achieve sufficent robust conclusions regarding long-term effect and equipotency. 
There is still not enough data to conclude that ERT can effectively prevent 
progressive kidney damage in the long run, and the need for a continuous update of 
unbiased treatment data in a central registry is mandatory (60). 
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1.1.6. Biomarkers 
Specific biomarkers in Fabry disease are GL3 in plasma and urine. Urinary GL3 and 
plasma GL3 are not ideal markers, and may be overlapping with normal levels 
especially in heterozygote women (61). The new biomarker lyso-GL3 is promising 
and correlates with disease activity in some patients, but not in all (e.g. some patients 
with late onset and in heterozygotes) (57, 62, 63). Measurement of GL3 deposits in 
tissue biopsies from kidneys and skin is an invasive procedure, and therefore many 
centres refrain from biopsies. Semiquantitative scoring has been the method of 
preference in the evaluation of renal biopsies from Fabry patients (38-40, 43, 54, 55). 
The most comprehensive and systematic attempt to establish a standardized scoring 
system of potentially prognostic markers in Fabry nephropathy was undertaken by 
the International Study Group of Fabry Nephropathy (ISGFN) in a group of 59 
patients (mean age 39.4 ± 13.2 years) (35 males) with mild to moderate nephropathy 
in CKD stage I and II, the mean eGFR was 81.7 ml/min/1.73 m2 and urine protein to 
creatinine ratio was 122.0 mg/mmol). Both disease-specific (lipid depositions) and 
unspecific general lesions of progression (fibrosis and sclerosis) were defined and 
showed a surprisingly wide spectrum of appearance even in clinically mild disease. It 
was anticipated that the scoring system would be useful for longitudinal assessment 
of prognosis and responses to therapy for Fabry nephropathy (5). Recently, a more 
quantitative and unbiased method has been introduced using stereologic 
morphometry (64), but all morphologic scoring attempts are hypothesis generating up 
to now and need confirmatory studies and assessment of follow-up studies in 
untreated and treated patients across several CKD stages and phenotypes. 
In many centers MRI of the brain and heart, echocardiography, audiometry and 
measurements of thin fiber neuropathy are objective measurements and part of 
routine assessments of the individual total disease burden, but many of these 
examinations are relatively insensitive and often normal in the young Fabry disease 
population.  
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In the regular follow-up of enzyme treated and untreated patients clinical assessment 
and anamnesis is important, and visual analogue scale questionnaires  (quality of life, 
intensity of pain and gastrointestinal symptoms) have been used systematically in the 
routine examinations and in many studies. However, such questionnaires should be 
evaluated with care as only few studies in adults have been placebo controlled (44, 
45). Measurements of kidney function and general clinical assessments are usually 
done simultaneously and are complementary parameters in the routine assessments of 
Fabry disease patients. In most centers kidney function measurements are routinely 
based on serum creatinine and creatinine based estimated GFR, as well as different 
methods for assessment of albuminuria/proteinuria. Creatinine based methods are 
subject to caveats and are insensitive when it comes to the diagnosis of early 
progressive kidney dysfunction, the so-called “creatinine-blind window”, a 
phenomenon that is particularly relevant in Fabry disease where ERT probably 
should be initiated before progressive dysfunction occur. Most follow-up protocols 
therefore recommend yearly examinations or 6 months intervals as a standard in 
otherwise stable patients. In line with all kidney disease patients, such standard 
follow-up routines are subject to variation according to the patient`s disease 
symptoms.  
 
1.1.7. Research in orphan diseases  
The use of potent and potentially toxic drug intervention is increasing in many 
common as well as rare renal diseases. In fact, many biotechnology companies 
prioritize development of orphan drugs where modern research are subject to strict 
surveillance imposed by detailed legislation, also in children (65). 
The number of rare disorders is estimated to be 6000-8000 affecting about 55 million 
people in Europe and the US (66). Rare disease in the US is defined as a disease 
affecting less than 200 000 inhabitants in addition to being life threatening and 
chronically debilitating, e.g. 6.5 patients per10 000 inhabitant, and in the EU 5 
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patients per 10 000 inhabitants (47). In Norway, a rare disease is defined as affecting 
less than 1 per 10 000, i.e. less than 500 cases per disease. Special regulations 
stimulating research on orphan diseases were introduced in the US in 1983, in Japan 
in 1993 and in the EU in 2000 (47, 67). The number of orphan drugs approved for 
use in children has been increasing (68). 
The Food and drug administration (FDA) and the European Medical Association 
(EMA) have recently presented guidelines that highlight the importance of 
meticulous safety and follow-up control of tolerance and side effects of new medical 
treatment also in children. Since 2007 new regulations from EMA have instructed the 
drug providers to make a pediatric investigation plan (PIP), and high quality research 
on therapeutic drugs to children has recently been focused (69). Instead of previous 
general reluctance to allow childrens participation in clinical trials, children should 
now be protected through clinical trials and should not be regarded “small adults”. 
Hence, this fundamental change of attitude should also be reflected in the use of 
relevant clinical methods subjected to evidence based risk and safety evaluation, also 
when it comes to indication for functional measurements and renal biopsies. 
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1.2. Evaluation of chronic kidney disease 
The key parameter in the assessment of chronic kidney disease is the measurements 
of glomerular filtration rate (GFR), and quantitative definitions (CKD-stageing and 
albumin-creatinine ratios in urine samples) have greatly improved diagnosis and 
treatment of kidney diseases. Supplementary information about structural (e.g. 
ultrasonogaphic or radiologic imaging and kidney biopsies) and functional (e.g. 
hematuria, proteinuria and GFR) kidney damage is necessary in the characterization 
of early kidney disease (CKD stage 1-2), and is of paramount importance in the 
diagnosis and risk stratification of individual CKD-patients (e.g. magnitude of 
proteinuria). 
Chronic kidney disease is defined as kidney damage (structural abnormalities or 
damage markers in blood or urine) or renal failure defined as GFR) reduced to < 60 
ml/min/1.73 m2 lasting for three months or more. A staging of chronic kidney disease 
in five levels was defined in 2002 by the Kidney Disease Outcomes Quality Initiative 
(K/DOQI) (70) (Table I).  
 
Table I: Chronic kidney disease stage 1-5 (modified from reference (70)) 
Stage Description GFR (ml/min/1.73 m2) 
1 Kidney damage with normal or  GFR ≥ 90 
2 Kidney damage with mild   GFR 60-89 
3 Moderate    GFR 30-59 
4 Severe    GFR 15-29 
5 Kidney failure < 15 (or renal replacement therapy) 
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This staging has paved the way for the increasing recognition that CKD is an 
important public health problem affecting 10 – 13 % of the general population, with 
an increased risk of cardiovascular complications and death (71). During the latter 
decade much effort has concentrated on defining low- and high-risk groups of CKD 
patients with respect to risk of many complications (especially cardiovascular events) 
and progression to end-stage renal disease (ESRD), an example of high-risk patients 
is co-existent hypertension, cardiovascular disease, diabetes mellitus and especially 
the combination of lower GFR and proteinuria (72, 73). Estimated GFR and 
albuminuria have been shown to be independent predictors for progression of kidney 
disease to ESRD (73), and even low levels of albuminuria is associated with 
progressive nephropathy in diabetes mellitus patients (74). In fact, the recognition of 
increasing levels of albuminuria/proteinuria is important both in the diagnosis and as 
a target of therapy in kidney diseases (75). 
The knowledge of the associated high risk of complications in CKD-patients, also 
including infections and cancer, lead to an updated position statement by the KDIGO 
Board of Directors in 2007, highlighting the importance of continuous focus on risk 
factors, as well as prophylaxis and early treatment of complications in the follow-up 
of CKD patients (72). Reduced GFR without accompanying risk factors often carry a 
good prognosis, and screening the general population for kidney disease therefore is a 
controversial issue. However, by combining eGFR and urine albumin excretion 
Hallan et al. showed that 2/3 of patients with progressive kidney disease could be 
detected. They stated that urinary albumin excretion is a marker of the rate of kidney 
disease progression, whereas eGFR is a marker of how advanced the kidney disease 
is (73). 
 
1.2.1. Glomerular filtration rate (GFR) 
GFR is the key parameter in the evaluation the kidney function, and creatinine 
measurements in serum and urine have been the basis for kidney function 
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measurements for many decades. The clearance of creatinine was for the first time 
measured by Rehberg in 1926 and in 1951 Homer Smith established the method and 
described its potential and limitations as a renal function parameter (76). The gold 
standard method for measuring GFR is inulin clearance, performed by continuous 
infusion of inulin and timed collection of urine samples via bladder catheter (77). The 
method, which was introduced by Earle and Berliner in 1946 (76), is time consuming 
and not feasible nowadays since inulin is not available. Several new gold standard 
methods have been adopted, and plasma clearance of adequate filtration markers ad 
modum Sapirstein (78) and Chantler (79) are based on timed blood samples and have 
been validated as alternative gold-standard methods. These methods have later been 
further simplified by Brochner-Mortensen in 1972 (80) and Jacobsson in 1983 (81). 
The commonly used substances Chrome-Ethylene Dinitrilo Tetra Acid (Cr-EDTA), 
technetium-99m-Diethylene Triamine Pentacetic Acid (99mTc-DTPA) Tc-DTPA and 
I-iothalamate are radioactive agents, and repeated use is often avoided due to concern 
of long-term detrimental consequences (82). The non-ionic radiocontrast agent 
iohexol is an ideal filtration marker and was introduced in the 1980’s (83), and is 
most widely used in Scandinavia and Italy. The safety of iohexol has been well 
documented (84-86), and iohexol-GFR-measurements are shown to correlate well 
with inulin-GFR-measurements (87-89). 
Estimated GFR measurements are calculations based on single blood sample 
measurements mainly of serum creatinine, and different formulas have been 
constructed for adults and children. The original formulas were primarily developed 
for adult patients with CKD stage 3-5, where eGFR show better correspondance with 
measured GFR. In the 1970’s and 1980’s the majority of formulas for estimating 
GFR was based on serum creatinine and body length, plus eventually age and sex in 
children (90-92). Later formulas including body weight have been developed (93), 
and cystatin C based estimations have been tested both in children and adults (94, 
95). However, cystatin C based formulas have not been universally adopted, mainly 
because of lack of consensus about standardization, and the cost is higher than 
creatinine-based measurements. Recently, substantial efforts have been reported to 
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improve and standardize the methods of analyzing creatinine in blood. Especially in 
children great variability in the broadly used Jaffe method has been demonstrated, 
and the calibration of both enzymatic serum creatinine analysis as well as the 
compensation of the Jaffe analysis to the Isotope Dilution Mass Spectrometry 
reference method (IDMS) results in 10-20 % lower values of serum creatinine 
compared to the previously widely used creatinine methods in the original 
methodologic reports of eGFR in children (96-98).  
By comparison with iohexol clearance as gold standard method, Schwartz et al 
recently constructed new formulas and subsequently validated the new and old 
formulas in children with CKD stage II-V (99). At the same time a new improved 
equation for GFR in adults was published: the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation (100) showing better performances than the 
broadly used Modification of Diet in Renal Disease Study equation (MDRD) (101), 
especially in the normal and higher levels of GFR. 
In the general CKD population, the eGFR formulas have proved to be valuable tools 
in the risk stratification for associated complications (especially cardiovascular 
complications) across all CKD-stages (71). However, it has not been proven whether 
the same predictive capacity is valid in smaller cohorts with specific diseases, e.g. 
Fabry disease. Furthermore, it is well known that the precision and accuracy of 
formula GFR may be lower in patients with high or low body mass index (102, 103), 
the latter is often the case in Fabry disease. 
In Fabry disease, formula based GFR estimation are used in the majority of renal 
function studies, usually the Modification of Diet in Renal Disease Study equation 
(MDRD) in adults (104) and the original Schwartz formula in children (91, 92, 105). 
We have previously shown that these formulas overestimate mGFR in children and in 
adult males, and these methods may also falsely indicate hyperfiltration in many 
patients, an observation that was strengthened by simultaneous measurement of 
normal GFR (102, 106, 107) (Figure I and Table II). These methodologic caveats 
may lead to the erroneous assumption that GFR is normal or falsely high in patients 
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where measured GFR discloses a borderline normal or early decline of GFR. 
Furthermore, serum creatinine usually will be normal in such cases with CKD stage I-
II, due to the insensitivity of creatinine and creatinine-based equations (i.e. the 
“creatinine-blind window”) to discover subtle decreases in true GFR.  
 
Figure I:  Difference eGFR-mGFR (95 %CI) in children and adults (blue bars: 
MDRD formula, green bars; Cockcroft-Gault (CG) formula, black bars; original 
Schwartz (S) formula, purpel bars: Counahan-Barratt (CB) formula) (107): 
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Table II: Comparison eGFR vs mGFR  (107): 
 
 
1.2.2. Urine tests 
Urine dipsticks, urine microscopy and quantitative measurements of albuminuria, 
proteinuria and classification of proteins of glomerular or tubular origin, are 
important examinations in patients with various kidney diseases. The methodology in  
the ascertainment  of urinary excretion of proteins have been changing from 
qualitative to quantitative methods which are important for diagnosis as well as 
targets for treatment (73, 75). 
The use of spot urine samples was introduced in the eighties (108), and protein-
creatinine-ratio in morning void urine has been shown to correlate well with 24h-
urine protein excretion (109). The use of protein-creatinine-ratio (PCR) and 
albumine-creatinine-ratio (ACR) was introduced as a routine measurement in Norway 
ten years ago (110, 111). The definition and implementation of various test methods 
is highly different in many publications and most clinical studies over the later 
decades refer to 24 hour protein-excretion. A recent report by Lamb et al. (112) has 
given a comprehensive overview of various methods and guidelines used for 
assessing urinary albumin and protein excretion (Table III). They suggest that 
quantitation of albuminuria should be the preferred method, as has been the case for 
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many years in the staging and monitoring of progressive diabetic nephropathy (113). 
The relevance of comparing diabetes mellitus and Fabry disease has recently been 
highlighted by Alberto Ortiz`s research group, demonstrating similar activation of 
detrimental and protective signals in the podocytes in models of the two diseases 
(114, 115). 
 
Table III: Different guidelines for assessing albuminuria/proteinuria (Table modified 
from reference (112)). 
 
The benefit of regular assessments of albuminuria as a predictive biomarker for 
various complications in the general population was highlighted in a recent 
metaanalysis in Lancet. Mutsushita and colleagues showed that albumin-creatinine 
ratio with a cut off value as low as 1.1 mg /mmol creatinine was an independent 
predictor of all case mortality as well as cardiovascular mortality (116). The use of 
micro- and macroalbuminuria in addition to GFR-level improves the prediction of 
disease progression substantially (73). An albumin-creatinine ratio as low as ≥ 0.75 
mg/mmol has been shown to be associated with cardiovascular morbidity in a 
Norwegian study of the general population (117). Furthermore, increasing levels of 
 
Guidelines Diabetes Mellitus (DM) Definition proteinuria in nonDM 
 
NKF-KDOQI (2002) ACR PCR > 23 mg/mmol 
 
CARI (2004) ACR u-protein > 150-300 mg/24 h 
 
KDIGO (2005) Albumin  
(ACR or albuminstrip) 
 
ACR > 3.4 mg/mmol 
 
SIGN (2008) ACR PCR > 100 mg/mmol 
 
NICE (2008) ACR ACR > 30 mg/mmol or 
PCR > 50 mg/mmol 
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albuminuria assessed by spot urine measurements have recently been shown to 
predict reduction in life expectancy in a huge population-based study in Canada 
(118). 
There are greater day-to day variations in albumin/protein-excretion estimated by 
spot urine compared with 24 hour estimates (119). Therefore a collection of three 
consecutive morning void urines samples are preferred, and the median value is 
judged to be the representative one (111).  
 
1.2.3. Kidney biopsies 
1.2.3.1. History and frequency of kidney biopsies 
Renal biopsies have been done for more than a century (120) and the percutaneous 
methodology was introduced and established in the 1950s (121-123). The technical 
advancements in imaging methods have evolved from indirect visualization to direct 
simultaneous real-time ultrasound guidance of the biopsy needle. The construction of 
automated spring-loaded devices by the end of the1980s (124-126) has replaced the 
manual aspiration methods and manual true-cut needle procedure. The modern biopsy 
techniques have improved the precision and efficacy of the procedure, and even more 
important, have reduced the frequency of procedure related complications (127).  
Knowledge of the histology from kidney biopsies is shown to alter the treatment in a 
high percentage of the patients (123, 128, 129), and the acknowledgement of the 
importance of kidney biopsies was in fact an important factor that lead to the 
establishment of nephrology as a subspecialty in 1960 (130). Generally, in many 
renal diseases there is a lack of valid early biomarkers. The role of kidney 
morphology as an important prognostic and therapeutic guide in common renal 
diseases has been convincingly demonstrated; e.g. diabetes nephropathy (131), IgA 
nephritis (132), lupus nephritis (133) and in orphan diseases like Fabry disease (5, 
49).  
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The annual rate of kidney biopsies varies from country to country dependent on the 
traditions and guidelines for performing a renal biopsy. In Australia there has been a 
relatively liberal indication for renal biopsy including isolated microscopic hematuria, 
and the frequency of native kidney biopsies (excluding transplants) has been reported 
23 per 100 000. In Italy 3.3 per 100 000 has been reported (1993), and in France 16.2 
per 100 000 (1990). In children, Australia has reported a biopsy frequency of 7 per 
100 000, and Italy 1.7 per 100 000 (134). In the USA, 7.5 native renal biopsies per 
100 000 per year has been reported (personal communication Richard Glassock). In 
Norway the overall frequency of renal biopsies has been intermediate compared with 
many other countries, and the average has been largely unchanged (about 11 per 
100000) in the period since the establishment of the Norwegian Kidney Biopsy 
Registry in 1988 (135). A higher threshold in some countries for performing a renal 
biopsy, especially in children, may be related to general concern over complication 
rates and legal consequences of complications. On the other hand, it is well known 
that kidney biopsies are often essential in the diagnosis and follow up of specific 
renal diseases also in children (136). 
 
1.2.3.2. Indications for kidney biopsies 
The variations in frequency of kidney biopsies are partly explained by 
differences in indications and procedural methods. In addition, indications and kidney 
disease spectrum have changed over the years, e.g. patients with isolated hematuria 
were more frequently biopsied in the 1990s than during the later decade according to 
data in annual reports from the Norwegian Kidney Biopsy Registry. Table IV shows 
recommended indications for a kidney biopsy (137), and Table V shows the current 
clinical indications that are reported in the patient data form (“K-skjema”) from 
Norwegian renal units to the Norwegian Kidney Biopsy Registry (one patient may 
have several positive tickboxes).  
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Table IV. Indications for kidney biopsy (137) 
Isolated glomerular hematuria 
Isolated nonnephrotic proteinuria 
Nephrotic syndrome; in adults, in small children when steroid resistent 
Acute nephritic syndrome 
Unexplained acute renal failure 
 
 
 
Table V. Indications for kidney biopsies reported in the patient data form to NKBR 
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In general, proteinuria is the most important sign leading to a kidney biopsy, but the 
definition of proteinuria and biopsy threshold is subject to variations from center to 
center, and from country to contry. Some centers argue that by isolated proteinuria 
urinary protein-creatinine-ratio should be > 3.5 g/g (396 mg/mmol) to indicate a renal 
biopsy whereas others have done general school-screening-programs performing 
renal biopsy if urinary protein-creatinine-ratio > 0.2 g/g (22.6 mg/mmol). A recent 
study showed that a renal biopsy may be indicated in isolated proteinuria when 
urinary protein-creatinine-ratio > 0.5 mg/mg (56.5 mg/mmol) (138).  
 
1.2.3.3 Complications and safety aspects of kidney biopsies 
In general, the risk of complications after a kidney biopsy is low when general 
contraindications (e.g. bleeding diathesis and hypertension) are respected, and the 
risk has been decreasing after the introduction of automatic springloaded biopsy 
devices and real-time ultrasound guidance (127). The most serious complications are 
uncontrolled bleeding necessitating surgical and/or radiologic vascular intervention, 
and deaths have been reported (139, 140). On the other hand, postprocedural 
perirenal hematomas are more or less obligate and often asymptomatic, occurring in 
up to 60-90 % of the procedures (126, 140-142). Most kidney biopsy studies 
comprise a limited number of patients, and there are few studies in children.  
Many kidney biopsy studies are published after 1990, and some metaanalyses are 
available. In 1991 Parrish reported a mortality rate of 0.12 % and surgery was 
performed in 0.29 % in  a review of more than 10 000 kidney biopsies performed 
since the 1950s (139). In 2002 Korbet reviewed a high number of newer publications, 
excluding the patients in Parrish’ study (140). Korbet found a rate of blood 
transfusions of 1.24 %, rate of surgery 0.23 %, and a mortality rate of 0.03 % in about 
7500 biopsies (140). An overview (personal review) of publications on safety of renal 
biopsies the last 20 years, not included in the two reviews above, shows a mean rate 
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of blood transfusions of 1.22 %, rate of intervention of 0.32 % and a mortality rate of 
0.02 % in a total of about 9500 biopsies (Table VI).    
Relative contraindications to performing a renal biopsy are severe hypertension 
despite adequate treatment, incorrectable bleeding diathesis, active renal or perirenal 
infection, hydronephrosis, solitary native kidney, small hyperechoic kidneys 
(indicative of chronic irreversible disease), multiple, bilateral cysts or a renal tumor 
(137). We have previously presented low kidney biopsy complication rates in 
children based on data from the Norwegian Kidney Biopsy Registry; 3.7 % of the 
464 patients had hematoma (which may not be regarded a complication per se), 2.1 % 
gross hematuria, and only one patient received blood transfusion. None of the 
patients needed surgical intervention, and there were no deaths (143) (Figure II). 
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Table VI: Major complications (intervention, transfusion, death) 
First author (year)  Biopsies 
performed 
N (T) Intervention 
N (%) 
Transfusion 
N (%) 
Death 
N (%) 
Al Rasheed (1990)* (144) 1982-1989 120 2 5 1 
Schow (1992) (145) 1985-1990 157 (28) 0 0 0 
Riehl (1994) (126) 1986-1992 458 (143) 2 - 0 
Richards (1994) (128) 1991 276 0 2 0 
Mendelssohn (1995) (146) 1992-94 544 (139) 0 3 0 
Bohlin (1995)* (147)  109 0 0 0 
Hergesell (1998) (148) 1993-97 1090 (114) 1 3 0 
Kersnik Levart (2001)* 
(141) 
1994-1999 88 0 0 0 
Whittier (2004) (149) 1983-2002 750 5 38 1 
Manno (2004) (150) 1995-2002 471 4 2 0 
Eiro (2005) (151) 1997-2001 394 0 0 0 
Shidham (2005) (152) 1981-2001 645 4 16 0 
Stratta (2007) (129) 1973-2002 1387 3 12 0 
Mackinnon (2008) (153) 2000-2007 1120 2 18 0 
Soares (2008) (154) 1996-2006 289 5 6 0 
Hussain (2010)* (155) 2005 531 (221) 1 4 0 
Mishra (2010) (156) 2006-2008 78 0 0 0 
Skalova (2010)* (157) 1997-2007 166 0 0 0 
Zhang (2011) (158) 2007-2009 280 0  0 0 
Torres Munôz (2011) 
(159) 
1998-2008 623 2 2 0 
Total 1973-2009 9576 31 (0.32 ) 111 (1.22 ) 2 (0.02) 
*children only . N; Number of biopsies performed, T; transplant biopsies included in the overall 
results 
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Figure II: Complications in children (143): 
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2. Aims of the thesis    
The aims of this thesis was to evaluate functional and morphologic renal disease in 
children and young adults with Fabry disease with and without enzyme replacement 
therapy by means of the currently best available routine methods for GFR assessment 
(ie. measured GFR and various creatinine-based GFR equations) (Study I), and 
assessment of disease specific and non-specific morphologic changes in kidney 
biopsies (Studies II and III). The safety and complications of kidney biopsies were 
evaluated in a large national cohort (Study IV). 
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3.  Material and methods  
3.1. Renal evaluation in young Fabry patients  
Among the patients with Fabry disease followed at Haukeland University Hospital a 
total of twenty-one young individuals, thirteen males and eight females, with a mean 
age of 15.4 ± 6.7,  range 5-33 years, were included in one or all of the three Fabry 
disease studies. In addition, in Study I, fifteen patients from Addenbrookes 
University Teaching Hospital, Cambridge, United Kingdom and thirteen from 
Department of Paediatrics, Academic Medical Centre, Amsterdam, the Netherlands, 
were included. The studies were approved by the Regional Ethics Committee of 
Western Norway (REK: 154.04. “Pasientoppfølging ved Fabry sykdom”. Project 
leader: professor Gunnar Houge), and were performed in line with the Declaration of 
Helsinki. All included patients and/or their designees signed informed consent. 
In Study I 42 patients, 24 girls and 18 boys, mean age 12.3  ± 3.6, range 2-17 years, 
from three Fabry centres in Bergen, Cambridge and Amsterdam were included. A 
total of eighty-two parallel eGFR- and mGFR-values were studied. eGFR was 
calculated with five different formulas based on serum creatinine values (90-93, 99): 
 
Counahan76: k x height(cm)/serum creatinine(mg/dl), k=0,43 (90) 
Schwartz76: k x height(cm)/serum creatinine(mg/dl), k=0,55, boys 13 years k=0,70 
(91, 92) 
Schwartz09: k x height(cm)/serum creatinine(mg/dl), k=0,413 (99) 
Leger02: 0,641(weight(kg)/serum creatinine(mg/dl)) + 16,063(height(m) 2/s-
creatinine(mg/dl)) (93) 
Leger09: 0,542(weight(kg)/serum creatinine(mg/dl)) + 9,948(height(m) 2/s-
creatinine(mg/dl)) (93, 99) 
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Serum creatinine was measured by an IDMS-traceable enzymatic method or by a 
Jaffe alkaline picrate method calibrated traceable to IDMS. The mGFR was measured 
by Iohexol single-point method at 4 hours (high performance liquid chromatograpy 
analysis) in the Norwegian patients, by Cr51-EDTA (three-point method; 2, 3 and 4 
hours) in the British patients and by iothalamate (four-point method; 1, 2, 4 and 6 
hours) in the Dutch patients. Analytical imprecision (CVa) and intra-individual 
biological variation (CVi) of the GFR-measurements were evaluated (please find 
definitions of CVa and CVi in the description of the methodology in Paper I). Urine-
albumin excretion was measured as albumin-creatinine-ratio and values > 2.5 
mg/mmol creatinine were defined as microalbuminuria.  
In Study II and III eleven males and two females, mean age 17.3 ± 7.5, range 7-33 
years, had from one to three kidney biopsies performed. Three male patients had 
already received ERT for 2-3 years before the first kidney biopsy was performed. 
One female patient did not receive ERT and she was therefore not included in Study 
III. In addition seven patients without a renal biopsy were included in the baseline 
study to describe the spectrum of clinical findings in the children cohort followed in 
our centre.  
The kidney biopsies were described by an experienced nephropathologist (light 
microscopy of paraffin-embedded sections and McDowell fixated sections (toluidine 
blue, semithin) as well as electron microscopy). For the GL3-accumulation 
semiquantitative scores (0 to +++) were used (2, 3), and in Study III  the biopsies had 
an additional scoring of the GL3-accumulation in the podocytes based on the scoring 
system of the International Study Group of Fabry Nephropathy (ISGFN) (160). We 
also expanded the scoring model of the ISFGN-group by combining the scores of 
light microscopy of the paraffin embedded sections with the scores of the toluidine 
blue sections in a “composite score” to obtain an even higher number of scorable 
glomeruli and increase the representativity of the scoring. Parallel to the kidney 
biopsies, functional renal evaluation was performed by means of standardized triple 
urine-tests (albumin-creatinine-ratio and protein-creatinine-ratio) and GFR-
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measurements (plasma-clearance of iohexol). Additional clinical parameters were 
added to describe the spectrum and burden of general Fabry disease manifestations. 
For statistical analysis SPSS version 14.0 and 17.0 was used and a p-value of 0.05 
was considered statistically significant.Baseline data are given as mean with 95 % 
confidence interval. Differences between groups were analysed with one way 
ANOVA in Study I. In Study III differences between the groups were analyzed with 
unpaired two-sided t-tests or Mann Whitney U-tests, dependent on wether the 
distribution of the variables followed a normal distribution or not. Equality of 
variances was tested with Levene’s test and corresponding t-tests were used. 
Differences within groups were evaluated by paired t-test if normally distributed 
variables and with Wilcoxon matched pairs signed rank sum tests if variables were 
not following a normal distribution. Linear regression analysis was performed to 
explore correlations. In Study I bias is given as mean value of eGFR–mGFR for the 
different equations and as a measure of precision the standard deviation and 
interquartile range (IQR) for the differences between eGFR-mGFR values were 
calculated. Percentages of the eGFR results within 30 %, 20 % and 10 % of the 
mGFR results (P30, P20 and P10) were gives as a measure of accuracy. The concept 
of critical difference (CD), defined as the minimal difference needed between two 
consecutive measurements to conclude that the results are truly different, was used to 
evaluate longitudinal changes in individual consecutive measurements (161).  
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3.2. Safety and complications of kidney biopsies in the 
Norwegian Kidney Biopsy Registry  
The Norwegian Kidney Biopsy Registry was established by professor Bjarne M. 
Iversen in 1988 and since April 1988 clinical and histopathologic data have been 
registered for nearly all patients with a native renal biopsy in Norway, a country with 
a current population of 5.0 million inhabitants. Local nephrologists from 26 different 
hospitals report clinical data in a registry notification form, and histopathological data 
are reported by a limited group of nephropathologists in one centre (Haukeland 
University Hospital) who examines all the biopsies.  The Norwegian Kidney Biopsy 
Registry is authorized by the Norwegian Data Inspectorate and all included patients 
or their designees have signed informed consent. In the time- period 1988-2010 
clinical data were registered in 9645 cases. In 3.7 % of the reports information 
regarding biopsy-related complications was lacking and these cases were therefore 
excluded leaving 8573 adult and 715 paediatric cases (in total 9288 cases) for 
analysis of the procedure related complications and safety issues in the period from 
April 1988 through November 2010. 
Five different complication alternatives were listed in the report forms; ”hematoma”, 
“gross hematuria”, “blood transfusion” ,“surgery” and a free text field. When arterial 
embolization was noted in the free text field the case was included in the “surgery”-
group. The term “complications” used in the current study was defined as gross 
hematuria, blood transfusions and/or surgery/arterial embolization. The term “major 
complications” was confined to blood transfusions and/or surgery/angiographic 
embolization. The following variables were explored; age, estimated glomerular 
filtration rate (calculated with the MDRD formula in adults (104) and the revised 
Schwartz-formula in children (99), systolic blood pressure, proteinuria (u-protein  ≥ 
0.3 g/d or reported “proteinuria” or “nephritic syndrome”), hematuria (u-dipstick  ≥ 1 
or reported “hematuria” or “nephritic syndrome”), chronic kidney disease stage 3-5, 
(estimated glomerular filtration rate < 60 ml/min/1.73 m2), nephrotic syndrome (u-
protein ≥ 3.0 g/d and serum-albumin < 35 g/l or clinician marked “nephrotic 
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syndrome”), acute renal failure, biopsy needle size, number of needle passes, 
speciality of the doctor performing the biopsy and the hospital size (≥650 and <650 
biopsies in the study period corresponding to ≥ 30 or < 30 biopsies per year) . 
Statistical analysis was performed using the SPSS 17 package (SPSS Inc., Chicago, 
IL). A p-value of < 0.05 was considered significant. Student’s t-test, Mann–Whitney 
test and Pearson chi-square test were used for significance testing and all tests were 
two-tailed. Analysis of risk factors for major complications was performed by logistic 
regression analysis and unadjusted analyses as well as analyses adjusted for age and 
categorized glomerular filtration rate were performed.  
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4. Results 
4. 1. Estimated and measured glomerular filtration rate in 
children with Fabry disease 
The results and comparisons of estimated GFR (eGFR) and measured GFR (mGFR) 
in young Fabry disease patients in our centre showed that eGFR overestimated 
mGFR substantially (Paper II (2008)), falsely indicating hyperfiltration in several 
patients (Table VII and Figure III). This issue was further explored in Paper I (2010). 
 
Figure III: Estimated GFR (original Schwartz formula (91, 92)) overestimates GFR 
compared to GFR measured with iohexol clearance (iGFR) in all patients (p<0.001). 
Measured GFR was normal in all patients, while eGFR suggest hyperfiltration in 
several patients (Figure presented in poster at ASN Renal Week, 2005) (162). 
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Table VII: Laboratory data in 16 Fabry children. α-Gal: α-GalactosidaseA 
levels in serum (μkat/kg protein). mGFR: iohexol GFR. eGFR: estimated GFR 
(Schwartz formula, 1976). *protein concentration (g/L) 
 
Patient Sex (F/M) 
Age (yr) 
α-Gal Albumin-
ratio 
(mg/mmol) 
Proteinratio 
(mg/mmol) 
Serum 
creatinine 
(μmol/L) 
mGFR 
(ml/min/1.73m2 ) 
eGFR 
(ml/min/1.73m2 ) 
1 M7 2,4 4,8 28,3 40 106 151 
2 F11 16,8 6,0 <0,15* 45 105 196 
3 F14 11,1 1,2 7,0 50 90 158 
4 M16 0,7 6,4 11,8 59 107 149 
5 M17 2,0 3,0 10,5 61 112 164 
6 M18 3,3 11,8 28,4 77 96 138 
7 M12 3,8 0,6 9.0 58 103 129 
8 M16 8,6 1.3 10,4 64 112 161 
9 M11 2,7 3,8 13.0 49 120 145 
10 M10 3,0 1,6 12.0 49 - 140 
11 F13 17,5 1,9 6.0 62 - 125 
12 F14 13,4 1,1 <0,15* 59 91 138 
13 F14 13,2 0,8 <0,15* 72 - 109 
14 M5 3,0 1,7 <0,15* 57 - 97 
15 F16 19,2 2,0 6,0 72 - 112 
16 F9 11,5 1,9 15,0 37 - 162 
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In the 42 children  (mean age 12.3  ± 3.6, range 2-17 years) included in Study I, the 
mean baseline mGFR was 108 ±13.5 ml/min/1.73 m2, range 87-147 ml/min/1.73 m2 
and 19 % of the patients had microalbuminuria (Table 1, Paper I). Normal body mass 
index was present in 86 % of the patients. No correlation was seen between albumin-
creatinine ratio and GFR, age or gender, and there were no significant differences in 
body mass index and serum creatinine between the Norwegian, the British and the 
Dutch cohort. The mean mGFR was higher (p = 0.01) in the Dutch patients compared 
to the British patients. 
The mean eGFR overestimated the mean mGFR in four of five formulas: the 
Schwartz76-formula had a bias of 50.6 ± 26.1 ml/min/1.73 m2, the Counahan76-
formula 9.9 ± 20.0 ml/min/1.73 m2, the Schwartz09-formula 5.3 ± 19.4 ml/min/1.73 
m
2
, the Leger02-formula 12.1 ± 27.1 ml/min/1.73 m2 and the Leger09-formula -21.9 
± 21.7 ml/min/1.73 m2 (Table 2, Figure 1, Paper I). The findings were similar in all 
three centres, when the first examination of each patient was analyzed separately (n = 
42, data not shown), as well as when repeated examinations were compared for 
example; first vs second (data not shown). Inter quartile ranges, similar to standard 
deviations, were large for the mean values of eGFR-mGFR; the Schwartz76-formula 
had a inter quartile range of 31.5 ml/min/1.73 m2, the Leger09-formula 31.7 
ml/min/1.73 m2 and the Leger02-formula 35.3 ml/min/1.73 m2 (the largest variance), 
whereas the Counahan76-formula had a inter quartile range of 22.4 ml/min/1.73 m2 
and the Schwartz09-formula was the equation with the highest precision and had a 
inter quartile range of 21.7 ml/min/1.73 m2. The Schwartz09 formula also showed the 
best accuracy of all GFR estimates with 87 % of the values within 30 % of the 
mGFR-value (P30), 79 % within 20 % of the mGFR (P20) and 49 % within 10 % of 
the mGFR (P10) (Table 2, Figure 1, Paper I and Figure IV). 
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Figure IV: Difference eGFR-mGFR in 42 children with Fabry disease (163). 
 
 
 
The Counahan76-formula had P30 of 87 %, P20 of 76 % and P10 of 41 %, the 
Leger02-formula had P30 of 72 %, P20 of 54 % and P10 of 24 % and the Leger09-
formula had P30 of 71 %, P20 of 50 % and P10 of 24 %. The Schwartz76 showed 
very low P30-P10-values of 27 %, 11 % and 4 %, respectively. Bland-Altman plots 
show the uncertainty for the five different equations (Figure V). 
In the thirteen patients with three or more consecutive mGFR measurements no 
significant deterioration of kidney function was noted. Substantial variability by 
repeated measurements was found in both mGFR and eGFR (Figure 3, Paper I). The 
variance of mGFR was within the limits of the defined critical difference in 10 
patients, one patient (patient 5) showed a temporary decrease in renal function 
(probably due to measurement error) whilst two patients (patient 6 and 10) showed 
improved mGFR. Larger variations was found in eGFR; five patients (patient 1, 2, 7, 
8 and 10) showed substantial increases of eGFR compared with the expected values, 
while two patients (patient 3 and 11) showed deteriorating values. Only one patient 
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(patient 10) showed concordant changes (increased GFR) of both mGFR and eGFR. 
In 6 of 13 patients eGFR falsely signalled changes of the renal function (either 
decrease or increase of GFR outside the limits of critical difference), and did not 
detect an improved function for one of the two patients that had such findings by 
mGFR.  Patient 3 had a substantial discrepancy between the first mGFR and eGFR, 
whereas there was a lack of discrepancy at the second and third GFR measurement 
(Figure 3, Paper I).  
 
Figure V: Bland Altman plots. X-axis: (eGFR+mGFR)/2.Y-axis: mean eGFR-mGFR 
for the five eGFR equations (ml/min/1.73 m2). In the lower right panel data from all 
the equations are included in one figure. 
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4.2. Kidney biopsies in young Fabry patients 
The mean age of all the twenty patients with Fabry disease included in Studies II and 
III was 15.3 ± 6.7, range 5-33 years (seven females and thirteen males). Eye changes 
were present in 90 %, acroparesthesias in 85 %, gastrointestinal symptoms in 65 %, 
hypohidrosis in 60 %, angiokeratomas in 20 %, white matter lesions (cerebral MRI) 
in 15 % and left ventricular hypertrophy in 10 % (Table VIII, Table 1, Paper II and 
Table 3, Paper III).  
 
Table VIII: Clinical symptoms and findings 
Patient 
(age/sex) 
Eye 
changes 
Acro-
paresthesias 
Gastro-
intestinal 
symtoms 
Hypo-
hydrosis 
Angio-
keratoma 
White matter 
lesions on 
cerebral MRI 
Left 
ventricular 
hypertrophy 
M5 + + + + - - - 
M7* + + + + - - - 
F9 + - - - - - - 
M10 - + - - - - - 
M11* + + + + - - - 
F11* + + + - - + - 
M12* + + - + - - - 
F13 + - + - - - - 
F14* + + - - - - - 
F14 + + - - - - - 
F14 + + - - - - - 
M16* + + + + + - - 
M16* + + + + - - + 
F16 + - - - - - - 
M17* - + + + - - - 
M17* + + + + - + - 
M18* + + + + + + - 
M23* + + + + - - - 
M30* + + + + + - - 
M33* + + + + + - + 
*Renal biopsy performed in study II-III 
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Among the thirteen patients with renal biopsy in the two studies, seven males and two 
females were less than 18 years of age at time of baseline biopsy and four patients 
were young adult males aged 18, 23, 30 and 33 years (mean age 17.3 ± 7.5, range 7-
33 years). All male patients had very low alfagalactosidase-levels, and the two female 
patients slightly decreased levels. Mean alfagalactosidase was 4.9 ± 4.6, range 0.65-
16.8 μkatal/kg protein (normal reference 17.7 – 26.4 μkat/kg protein), mean plasma 
GL3 was 8.3 ± 3.0, range 2.6-13.1 (normal reference 1.6-3.3 μmol/L) and mean 
urinary GL3 was 4.7 ± 5.7, range 0.3-21.6 mol/mol (normal reference <0.6 mol/mol). 
Ten of thirteen patients (77 %) had microalbuminuria at baseline with mean 
albumine-creatinine-ratio 5.1 ± 4.0, range 0.59-13.6 mg/mmol creatinine and mean 
protein-creatinine-ratio 16.2 ± 8.1, range 7-28.4 mg/mmol creatinine. Mean GFR was 
104.6 ± 9.7, range 86-120 mmol/min/1.73 m2, and all but one 30 years old male 
patient had normal mGFR (Table 2, Paper II and Table 1, Paper III).  
The baseline biopsies showed white looking glomeruli in bedside stereomicroscopy 
in all patients due to the illumination of sphingolipids (GL3) in the podocytes in the 
surface-near glomeruli (Figure VI and Figure 1, Paper II). 
 
Figure VI: Stereomicroscopy, renal biopsy from 11 year old boy with Fabry disease 
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All patients had maximal score of GL3-accumulation in the podocytes when the 
toluidine blue stained semi-thin sections were examined by light microscopy (Figure 
VII, Figure 2, Paper II and Table 5, Paper III).  
 
Figure VII: Toluidine-stained semithin section, renal biopsy from 11 year old boy 
with Fabry disease 
 
 
 
 
 
 
 
 
 
In addition, examination with electron microscopy showed segmental foot process 
effacement in all thirteen patients as well as glomerular endothelial cell and 
mesangial cell inclusions in all patients except in the three males already treated with 
ERT before their baseline biopsy (Figure VIII, Table IX, Table 4, Fig 6, Paper II and 
Table 4, Paper III). Light microscopy of the Periodic-Acid-Schiff (PAS) sections 
showed vascular, interstitial and/or glomerular changes in nearly all patients (Table 3, 
Paper II); arteriopathy in 6/13 patients (Fig 3, Paper II), glomerular hyaline in 4/13 
patients (Fig 4, Paper II), interstitial fibrosis in 5/13 patients, global glomerular 
sclerosis in 5/13 patients and early sign of focal segmental glomerular sclerosis 
(FSGS) was seen in one male and one female patient (Fig 5, Paper II). The scoring of 
the vacuoles in the podocytes gave full or nearly full score in all patients. (Table 5, 
Paper III). 
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Figure VIII: Electron microscopy, renal biopsy from 11 year old boy with Fabry 
disease 
 
 
 
 
 
 
 
 
 
 
 
Figure IX: Periodic-acid-schiff section, renal biopsy from 11 year old boy with 
Fabry disease 
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Table IX: Scoring of renal biopsies; light microscopy and electron microscopy 
T: time of biopsy: 0 is baseline, numbers represent years after baseline. GS: Global glomerual sclerosis (number of GS/total 
glomeruli), FSGS: focal segmental glomerulosclerosis, Glom: glomerular, Interstit: interstial, Mes. Cell incl: GL3-inclusion 
in mesangial cells,  Glom.endot. Cell incl: GL3-inclusions in glomerular endothelial cells, Dist. Tub. Epith.Cell incl: GL3-
inclusions in distal tubular epithelial cells. *2 years of ERT at baseline, #3 years of ERT at baseline. #estimated 
semiquantitively and scored to nearest 5 %. NA: not available. The GL3-inclusions in the podocytes are given in values 0-7 
as composite podocyte scores based on scoring of the GL3-inclusions in toluidine-stained semithin sections (0-4) and 
scoring of the vacuolization of the podocytes (0-3), the scoring system of the International Study Group of Fabry 
Nephropathy (5). 
 
Twelve Fabry patients (mean age 17.6 ± 7.7, range 7-33 years) were treated with 
ERT in the study period for a median of 65, range 13-69 months. Three patients 
received ERT before baseline biopsy, and the total treatment-time with ERT was 68 ± 
22, range 13-99 months (Table 3, Paper III). There were no statistical significant 
differences between the baseline data in the “low-dose”-group (6 patients, agalsidase 
0.2 mg/kg/eow) and the “high-dose”-group (6 patients, agalsidase 0.4-1.0 
mg/kg/eow) (Tables 1-2, Paper III).  
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All patients had stable mGFR throughout the study period with a mean mGFR of 
107.3 ± 12.9 ml/min/1.73 m2 after a mean ERT of 60.3 ± 15.2 months (Table X and 
Figure 1, Paper III).  
 
Table X: Laboratory assessments 
ACR: albumine-creatinine-ratio, ref <2.5 mg/mmol, PCR: protein-creatinine-ratio ref < 20 mg/mmol, pGL3: 
plasma-triohexosid, ref 1.6-3.3 μmol/L, uGL3: urine-trihexosid, ref < 0.6 mol/mol * eGFR in child new 
“bedside”Schwartz formula, in adult CKD-EPI formula.  
 
Normalization of microalbuminuria was found in five patients ≤ 17 years, two 
remained normoalbuminuric and four patients ≥ 18 years had stable albumin-
creatinine-ratio (Table X and Figure 1, Paper III). One 17 years old male (patient 7) 
had an increase of microalbuminuria and de novo proteinuria (Table X and Figure 1, 
Paper III) due to combined glomerular and tubular damage shown by protein 
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classification. Two of four patients that had slightly elevated protein-creatinine ratio 
(25.1-28.4 mg/mmol) at baseline (Table X and Table 1, Paper III) normalized their 
proteinuria and the other two stayed in the same level. 41.7 % (5/12 patients) of the 
urinary GL3-values and 18.2 % (2/11 patients) of the plasma GL3-values normalized 
on ERT. Anti-alfagalactosidase antibodies were found only in patient 3 and 5; in both 
cases the titers were just above the cut-off-values and the elevations were transient.  
The re-biopsies after 5 years of ERT showed complete clearance of mesangial cell 
inclusions and glomerular endothelial cell inclusions in all patients (Table 4, Paper 
III). In seven of eight of the patients who had a repeat biopsy after 1-3 years this 
finding was also evident at this stage. Almost complete clearance of the podocytes 
was found in one patient, a male patient aged seven years at start of ERT (Figure 2-4 
and Table 5, Paper III and Figure X), and substantial clearance was found in another 
three patients. Gradual decrease in podocyte inclusions in biopsies after 1 and 5 years 
ERT was seen in patient 5 (Table IX, Table V, Paper III). Significant correlation of 
the decrease of podocyte scores was found with cumulative agalsidase dose as well as 
with change in ACR (Table XI and Figure 2 and 4, Paper III). No significant 
correlation was found between changes in podocyte scores and duration of treatment, 
clinical scores, age, or change of podocyte effacement. 
Patients in Group 2 (“high dose”) had a significant decrease of podocyte inclusions 
(p=0.037). The four patients with the highest ERT-doses (patients 1, 3, 5 and 9) had a 
decrease in podocytes-GL3-score of 2.84 (p=0.010), in composite podocyte-score of 
4.5 (p = 0.018) and in ACR of 4.2 mg/mmol (p = 0.005) and this change was 
significant greater compared with Group 1, p=0.004, p= 0.010 and p = 0.011 
respectively (Table 5, Paper III). The four patients with the greatest decrease in 
podocyte-GL3-score showed concomitant reduction of podocyte effacement. Among 
the patients with nearly no change of podocyte-GL3-score only two patients had less 
podocyte effacement (patients 8 and 11).  The change of urinary albumin-creatinine 
ratio correlated significantly with the change in podocyte-GL3-score (r=0.837, 
p=0.001) as well as with the composite podocyte-score (r=0.823, p=0.002) (patient 7 
was excluded due to mixed glomerular and tubular proteinuria) (Figure 4, Paper III).  
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Figure X: Stereomicroscopy of Fabry kidney tissue: A; patient 1, B; patient  2, C; 
patient 7, D; patient 9 (Paper III) 
 
 
Table XI: Linear regression analysis of change in podocyte-scores vs ERT-dosis and 
change in albumin-creatinine-ratio after 5 years ERT.  
The GL3-inclusions are given in values 0-4, the vacuolization scores are given in values 0-3, the combined 
inclusion- and vacuolization scores are given in values 0-7.  Albumine-creatinine-ratio (ACR), reference <2.5 
mg/mmol . (Patient 7 was excluded from the regression analyzis including albumin-creatinine-ration due to 
mixed glomerular and tubular proteinuria) 
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GL3-inclusions in the epithelial cells in the distal tubuli were cleared for GL3-
inclusions in two patients in the final biopsies, and both patients (patient 1 and 3) 
were treated for 5 years with agalsidase 1.0 mg/kg/eow. In four of the five patients 
with global glomerular sclerosis at baseline, no global glomerular sclerosis was found 
in the re-biopsies, and no de novo interstitial fibrosis emerged. Generally, 
arteriopathy remained unchanged in the group as a whole. 
 
 
4.3. Safety and complications of renal biopsies from the Norwegian 
Kidney Biopsy Registry 
The mean age of the 715 children included in the study was 12.0 ± 4.9, range 0.04-
17.9 years, and in the 8573 adult patients the mean age was 50.6  ± 17.7, range 18.0-
94.4 years. The clinical characteristics of the patients at the time of kidney biopsy 
were proteinuria in 81.0 %, hematuria in 68.8 %, CKD stage 3-5 in 61.6 %, nephritic 
syndrome in 28.7 %, acute renal failure in 18.6 % and rapidly progressive 
glomerulonephritis in 3.4 %. Nephrotic syndrome and hematuria were more common 
in children than in adults (p<0.001 and p=0.001, respectively), and chronic as well as 
acute renal failure were more frequent in adults (p<0.001) (Table 1, Paper IV).  
The frequency of gross hematuria was 1.92 %, of blood transfusion 0.85 % 
(significantly lower in children, p= 0.03) and invasive procedures (surgery or 
angiographic embolization) 0.19 %. Complications defined as one or more of theese, 
were present in 2.6 % and serious complications defined as blood transfusion and/or 
invasive procedures were present in 0.9 % (Table 2, Paper IV). Although the number 
of biopsies per year increased, the frequency of complications (gross hematuria, 
blood transfusion and invasive procedures) remained stable throughout the whole 
study period (Figure XI and Figure 1, Paper IV).   
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Arteriovenous fistula, urosepsis and ascites leakage were reported in one case each 
(free text field). Death was not reported in any patients. In 97.9 % of the cases there 
were no complications. 
 
Figure XI: Kidney biopsy comlications (blue: no complications, green: gross 
hematuria, yellow: blood transfusion, catheterbased embolization or surgery) 
 
   
 
 
 
 
 
 
 
 
 
In 82 % of the cases 16 G or 18 G needle was used (Table 3, Paper IV). Over time 
there was an overall shift from 14 G to 16 G size (Figure XII and Figure 2, Paper IV).  
The rate of major complications was similar across all needle types (Table 3, Paper 
IV), whereas a significant higher rate of gross hematuria was found in the 18 G group 
compared to the 16 G group. 
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The percentage of biopsies containing representative tissue was 94.3 % and was not 
related to the size of the needle. The lowest number of glomeruli was achieved when 
the 18 G needle was used; the mean number of glomeruli was 10.7, range 0-76, 
p<0.001. The mean number of glomeruli in all the groups together was 12.0 (range 0-
86).  In 3.0 % of the biopsies no glomeruli were found. In the majority of the patients 
only one (47.5 %) or two (37.9 %) passes were performed per biopsy procedure. 
 
Figure XII: Kidney biopsy needle sizes (blue: 14 Gauge, green 16 Gauge, Yellow: 
18 Gauge, Purple: Unknown) 
 
 
 
T 
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The risk factors for major complications were analyzed using logistic regression 
(Table 4, Paper IV). In children the relative risk was 0.4, and in the patients aged ≥ 60 
years the relative risk was 2.3 when compared to adults 18-59 years old. When 
adjusting for eGFR there was no correlation with age. In the patients with GFR 30-59 
ml/min/1.73 m2 the relative risk was 5.0, and in the patients with GFR < 30 
ml/min/1.73 m2 the relative risk was 16.8 compared to the patients with GFR ≥ 60 
ml/min/1.73 m2. Adjusting for age the relative risks were fairly unchanged; 4.9 and 
15.5 respectively. Higher blood pressures were associated with increased risk; a 
systolic blood pressure of 140-159 mm Hg or ≥ 160 mm Hg showed relative risks of 
1.5 and 2.3 respectively. Adjusting for both eGFR and age removed the significance 
of higher risk of higher blood pressure (odds ratio 1.1 and 1.3 respectively). In 
unadjusted analyses, acute renal failure had a relative risk of 2.29, in the adjusted 
analyses the odds ratio was only 1.1 (non significant). When less than 650 biopsies 
were performed in a centre during the whole study period, the relative risk was 1.9 
compared to the bigger centres (≥ 650 biopsies). In adjusted analyses the relative 
risks were 1.6. The level of proteinuria, diagnosis of rapidly progressive 
glomerulonephritis, needle size, number of passes and the type of medical specialty 
of the physician did not inluence the rate of major complications.  
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5. Discussion 
5.1. Methodological considerations. 
5.1.1. Functional renal measurements 
5.1.1.1. Glomerular filtration rate  
As in most previous Fabry disease studies the renal function in Study II was 
evaluated by creatinine based formula estimation of the GFR. In addition the renal 
function was measured with plasma clearance of iohexol for comparison of estimated 
GFR (eGFR) and measured “true” GFR (mGFR). To our knowledge Paper II was the 
first paper that presented a paired eGFR-mGFR evaluation in children with Fabry 
disease. This was further explored in a greater patient cohorth involving three centres  
in Study I. Three different mGFR methods were used that all are generally validated 
against the gold standard inulin-clearance and adopted as feasible modern gold 
standard methods (87, 89, 164-173). In addition, all centres have validated their 
preferred method locally and defined the accuracy (analytical variation) of the 
method in the respective laboratories. However, the use of different methodology of 
GFR-measurements is a limitation in Study I and ideally the same mGFR-methods 
should be used in all centres. To achieve our goal, the use of the different mGFR-
methods was the only way to demonstrate the difference between mGFR and eGFR 
in a relatively large cohort of children with Fabry disease. Fabry disease is a rare 
disease and therefore in many studies cooperation between centres in several 
countries is necessary to obtain a meaningful sample size. We believe our 
comparative data are valid because of similar validated accuracy of the three 
methods. Secondly, the median values for bias for the different equations were 
similar in all three cohorts in spite of the different methods used. We believe that the 
finding of similar normal GFR-levels and stable pattern over time strengthens our 
results. 
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The single-point Iohexol method used in the Fabry patients followed in Bergen is 
shown to correlate well with multiple point methods (89, 164-166), but there is a 
higher risk of outliers in the single-point method. Preliminary results in a Norwegian 
multiple-point iohexol study in children show that the single-point method is 
adequate in children above 10 years with various chronic kidney diseases (174).  
The “blind range” of serum creatinine is an important issue in the validation of 
creatinine based GFR methods, although attenuated this pitfall is not abolished by the 
use of creatinine-based GFR formulas. The renal function may be reduced as much as 
about 50 % before the serum creatinine value is above the upper reference value 
(175). One of our main objectives in this study was to highlight the fact that 
creatinine-based eGFR-equations, which have been the routine methods for follow-up 
of patients with kidney disease, have important limitations and should be used with 
care. The early identification of subtle decline of GFR is the most important point, 
since this may be a critical limit for the initiation of enzyme replacement therapy .  
 
The complex Schwartz formula includes cystatin C and blood urea nitrogen (BUN) in 
addition to creatinine, height and age (99). Many centres, including the three centres 
in Study I, do not have analyses of cystatin C in the routine, and in Fabry studies, i.e. 
published clinical trials and international Fabry Registries (Fabry Outcome Survey 
and Fabry Registry) cystatin C has until now not been validated. This is a relevant 
issue, since many Fabry patients have low body mass index that may influence the 
accuracy of current GFR-equations. Although the accuracy of the complex Schwartz 
formula is superior to the abbreviated formula, there still is a relatively great 
imprecision; 87.7 % within 30 % of mGFR, and only 45.6 % within 10 % (P10) (the 
values for the abbreviated Schwartz formula were 79.4 % and 37.0 % respectively). 
As plus-minus 30 % means a high absolute value in the normal ranges of GFR, the 
value within 10 % is important in this context; a change in GFR of 10-20 ml/min/1.73 
m
2
 would be highly relevant in the follow up of a child with Fabry disease. In our 
view the relatively low 10 % precision (P10) of both formulas is a matter of concern, 
and implies that the risk of missing an early decline in true GFR is relatively high. 
 60 
Again, this fact strengthens our routinely use of a more precise GFR method 
(iohexolclearance). Our definition and evaluation of bias, precision and accuracy are 
in line with others (99, 176, 177). 
There are studies that show that cystatin C-based formulas (94, 95) or formulas that 
combine cystatin C and creatinine (99, 178, 179) are superior to creatinine-based 
formulas alone. In studies of individuals with normal GFR without diabetes and/or 
cardiovascular disease cystatin C has not proved superior to creatinine (180), and the 
diagnostic accuracy of different cystatin C-equations varies with GFR-level (181). 
Comparison with cystatin C and cystatin C-derived equations is generally highly 
relevant when all available and refined GFR methods are compared, especially in 
children with low normal or marginally decreased GFR, which is a main focus in the 
follow-up of renal disease in Fabry patients. However, the feasibility of the cystatin C 
derived methods is under debate, and importantly, no reference method or uniform 
calibration material exists for cystatin C. In addition, the method is more expensive 
and certainly not a routine method in many hospitals (182, 183). This is in contrast to 
the routinely used creatinine-based equations that now are based on standardized 
analyses (IDMS-calibrated) which render comparisons with gold-standard methods 
more conclusive. In particular, the utility of modern cystatin C methods deserves 
specific clarification in Fabry populations. Unfortunatly, we did not have cystatin C 
measurements in our study. 
 
Few patients had three or more GFR-measurements in Study I and the follow-up 
period was relatively short which limits the value of comparison between repeated 
measured and estimated GFR measurements. Three or more paired mGFR-eGFR 
measurements were available for 13 patients. These patients all had stable renal 
function and we think that the minor variations seen in repeated measurements are 
due to analytical and biological variation. The concept of critical difference was used 
to evaluate the difference observed between repeated measurements, and defines the 
minimal difference needed between two results to conclude that there is a true 
difference not due to the within-subject biological variation and the analytical 
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variation (161). This is a valuable tool in the assessment of clinically important 
changes. 
 
5.1.1.2. Albuminuria 
Three morning void urine samples (three consecutive days) were collected from the 
patients and the median value was used to obtain a standardized procedure and avoid 
the problems of intra-individual variation in urine albumine excretion. The use of the 
mean value would introduce the risk of results indicating microalbuminuria based on 
one single outlier. The cut-off value of our clinical laboratory was > 2.5 mg/mmol 
creatinine both for men and women (111). Due to the higher muscle mass in males 
some centres recommend a cut-off value of > 3.4 mg/mmol creatinine in females 
(112). On the other hand, only one female patient in Study II and Study III had 
microalbuminuria (ACR 6 mg/mmol). Gubler et al. reported 3 pediatric cases (8, 11 
and12 years old) with 0 mg/min proteinuria (2). Four of their adult patients (above 20 
yr) had proteinuria in excess of 0.6 mg/min (720 mg/24 h)(2). Probably 
microalbuminuria was not measured, and they do not describe the protein method 
used. Generally, protein assays are less sensitive than albumin methods. 
Three patients (patient 5, 7 and 11) received treatment with angiotensinII-receptor-
antagonist after the baseline biopsy. Despite this additional renoprotective treatment 
the ACR-values increased in one (patient 7), whereas the microalbuminuria 
normalized in one (patient 5) and remained stable in one (patient 11). Consequently, 
the use of angiotensinII-receptor-antagonist did not influence microalbuminuria in an 
unequivocal direction in these few cases. We do not believe that these cases have 
critical influence on our results. 
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5.1.2. Kidney biopsies     
5.1.2.1. Kidney biopsies in Fabry disease 
A limited number of Fabry disease patients were studied (in total 13 unique patients) 
in Study II-III. The rather small number of patients in our studies were a consequence 
of the rarity of Fabry disease and the fact that both studies were single-centre studies 
based on the consecutive inclusion of patients referred to the specialist team at 
Haukeland University Hospital. The Fabry Group at Haukeland University Hospital 
shares with Oslo University Hospital the responsibility for diagnosis and treatment of 
patients with Fabry disease in Norway (46). The diagnosis and follow-up of patients 
is performed in line with our local Fabry-protocol that includes a multispecialist 
team. The recommended examinations include initial mutation analysis and specific 
enzyme and glycosphingolipid analyses, routine laboratory tests, renal function tests, 
cardiac examinations including echocardiography and cardiac and cerebral MRI, 
audiogram, eye examination and neurologic examinations. Kidney biopsies may 
sometimes be of decisive diagnostic importance in patients with unknown kidney 
disease, and is recommended in the local Fabry-protocol to assess baseline kidney 
damage in patients where ERT is initiated. Because of the scarcity of scientific data 
in patients on ERT with early nephropathy and low total disease burden, we wanted 
to include all available patients in a systematic review of morphologic and clinical 
data to obtain new knowledge of indication and effect of ERT. All patients were 
enrolled on a consecutive basis, and choice of enzyme treatment (Paper III) was 
balanced to gain experience with both available medications (agalsidase alfa and 
agalsidase beta) in their respective licensed doses.  
The majority of clinical trials in children with Fabry disease treated with ERT have 
mainly focused on safety aspects as well as quality of life and renal biopsies have not 
been done in any previous studies (184-187). Only a few pediatric Fabry cases with 
renal biopsies have been reported in the literature, and they were all without ERT (2). 
Generally, there has been a reluctance to perform renal biopsies in Fabry disease 
children in many countries, whereas in Norway the threshold for renal biopsy has 
 63 
been lower based on clinical experience and safety data from the Norwegian Kidney 
Biopsy Registry (135, 143). The ERT is financed through the public health care 
system in Norway, and the treatment is evaluated through yearly applications to 
HELFO (www.helfo.no) from the responsible doctors on behalf of the different 
patients.  
All pediatric Fabry disease patients on ERT in Norway are followed at Haukeland 
University Hospital, and the patients were recruited to the Study II and III on a 
consecutive basis. The inclusion also of young adult males with mild renal disease in 
Study III allowed statistical comparisons between various treatment regimens in a 
patient cohort of still relatively young patients with rather low total disease burden 
and without evidence of irreversible organ damage. Such a patient cohort with rather 
“early disease” is markedly different from the many other long-term follow-up 
studies comprising many patients with more advanced disease (49, 188-191). There is 
a lack of studies that evaluate disease progression and ERT effectiveness in young 
patients, and no clear guidelines have defined a proper timing when ERT should be 
initiated. Ideally, a randomized double blind clinical trial should have been performed 
to compare doses and drugs in Fabry disease. However, such randomized double 
blind clinical trials are difficult to perform for many reasons; Fabry disease is a 
multisystemic disorder with a mixture of phenotypes, the drugs have been on the 
marked for more than ten years, and the treatment is subject to local experience. No 
such trials have yet been demanded from the health authorites.  
Our re-biopsy study was an observational study taking into account the fact that both 
preparations have been available in Norway since 2001 (32, 192), and many of the 
patients were involved together with the doctors in the choice of treatment drug. The 
different dosing regimens are subject to different infusion procedures which also have 
practical implications for the patients; standard dose agalsidase alfa is normally given 
over 40 minutes whereas standard dose agalsidase beta initially is given over 4-5 
hours reduced over months to a minimum of 1.5 hours (46).  
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After more than ten years of ERT there still is uncertainty as to the equipotency of the 
two available enzyme preparations (agalsidase alfa and agalsidase beta) in their 
licensed doses, although several experimental studies and clinical observations 
suggest that they may be similar mg per mg (53-56, 58, 62, 193). Both Blom et al. 
and Lee et al. have shown functionally indistinguishability between the two 
preparations (51, 194). Sakuraba found a higher enzyme activity by agalsidase beta in 
cultured human Fabry fibroblasts and kidney, heart and spleen when the same doses 
were given of agasidase alfa and agalsidase beta (52). Our hypothesis was that 
morphologic examinations of various kidney cells before and after ERT for a 
sufficiently long time period might have the capacity to discover dose-dependent 
differences in the clearing of GL3-deposits. The potential biomarker role of kidney 
biopsies in Fabry disease is even more important since this method has a potential for 
discovery and grading of reversible damage and treatment effects (GL3-inclusions) in 
a phase of clinical silence (normoalbuminuria and normal serum creatinine). 
Moreover, if such important treatment decisions should be delayed until manifest 
proteinuria or progressive kidney dysfunction (GFR < 60 ml/min/1.73 m2) occur, 
many patients will be in a phase where treatment is ineffective or suboptimal with 
uncertain long-term ERT benefits (49).  
The scoring of the renal biopsies in clinical trials in adults supported by either 
Genzyme or Shire/TKT 5S has been performed by three different pathologists (44, 
45, 48-50, 195). For our single centre observational studies, not supported by the 
industry, one experienced independent renal pathologist was responsible for the 
consecutive evaluation of the renal biopsies and this pathologist was blinded to which 
kind of medical treatment the patients received. In Study III a second renal 
pathologist blinded for the identity, treatment and order of the biopsies to secure 
unbiased scoring, re-scored the GL3-inclusions in the podocytes using the scoring 
system of the International Study Group of Fabry Nephropathy (ISGFN) from 2010 
(160). Both the scoring of the GL3-inclusions in the podocytes evaluated in 
McDowell-embedded tissue as semithin toluidine-blue sections as well as the scoring 
of the podocyte-vacuoles in PAS-sections from paraffin-embedded tissue was 
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included in the examinations of the biopsies. The paper of the ISFGN did not 
combine the scoring of the GL3-inclusions in the toluidine stained sections and the 
scoring of the vacuolization in the PAS-sections (5). Due to the fact that the 
vacuolization in the PAS-sections represent the space where the GL3-lipid was 
located before the fixative was applied, the additional information from the PAS-
sections is a valuable supplement to the information found in the toluidine-stained 
semi-thin sections. We therefore postulate that the use of a “composite score” 
introduce a higher degree of representativity since the scoring then is based on a 
substantially higher number of unique glomeruli. Based on this, we chose to expand 
the scoring methods reported by ISGFN and included a “composite score” to take 
advantage of as many scorable glomeruli as possible. This is an important issue since 
sampling error always is a confounder in the characterization of renal morphology, 
especially in the assessment of non-homogenous changes.  
A separate table (Table 5, Paper III) shows the scoring of the GL3-inclusions in the 
toluidine-stained semithin sections (0-4) and the scoring of the vacuolization in the 
PAS-sections (0-3). It is a reassuring finding in our study that both scoring methods 
showed similar significant dose-dependent effects in the treatment induced reduction 
of deposits. In this table, as well as in Table 6, Paper III, we also chose to include the 
composite score (0-7), and we suggest that the combination of the two scores (GL3-
inclusions and vacuolizations) is a more valid marker of renal disease progression and 
a potential sensitive biomarker for assessment of adequacy of ERT in terms of renal 
morphologic damage. The mean number of scorable glomeruli in PAS-sections at 
baseline was 18.8 ± 7.8 and after five years 15.3 ± 6.4, and in the semithin blue 
stained sections 9.3 ± 8.2 and 6.0 ± 3.9, respectively. 
The semiquantitative method used to score the biopsies has been a standard in 
evaluation of Fabry disease in line with many other kidney diseases (2, 5, 48, 49, 
196). The purpose of the ISFGN-paper was to develop a standardized scoring system 
of baseline kidney biopsies with potential use also for longitudinal assessment of 
prognosis and responses to therapy. The podocyte scores (both vacuoles and 
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inclusions) were among the most robustly scored elements with reasonably well 
agreement between nephropathologists (5). Our Paper III is the first study where this 
scoring method has been evaluated for follow-up, and confirmatory studies are 
needed. However, the ISFGN-paper is the only validated evaluation of a standardized 
scoring system of Fabry disease specific renal pathology.  
A more quantitative analysis of the number of inclusion bodies and assessment of 
differences in size and structure at least at the level of semi-thin plastic sections, in 
the various glomerular cells, in selected segments of the tubules, endothelial cells in 
peritubular capillaries, and the cells of the vascular wall would have been of interest, 
but this is not an available routine method yet. A stereologic morphometric 
methodology has recently been tested in Fabry patients not treated with ERT (64), 
and for finer staging and more detailed evaluation of dose-response effectsof ERT, 
morphometric methods will probably give valuable additional information. On the 
other hand, this issue will also be subject to considerable research and need 
methodologic evaluations in larger patient groups. Electronmicrographic 
examinations are normally based on only one glomerulus, and the issue of 
representativity is an argument against giving electron micrograph based on a single 
glomerulus high weighting in this context.  
Because of the limited number of patients we chose to compare one “low dose” group 
and one “high dose” group, the latter also included three patients with “intermediate 
dose” (0.4 mg/kg/eow). Given the assumption that a dose-dependent effect exists and 
that the drugs are similar on a mg-to-mg basis, this is in our opinion the only 
reasonable way of dividing these patients for initial comparison. We believe the renal 
response of treatment is hard to evaluate in a sufficiently accurate manner based on 
eGFR and urine tests alone due to the insensitivity of these methods (e.g. creatinine 
blind range) (103, 197) and the fact that Fabry disease per se is a disease that varies 
very much even in male patients with the same mutation. Morphologic characteristics 
also have the potential to predict future development of albuminuria or loss of renal 
function and morphological changes are probably the earliest sign of renal damage 
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that could be identified in these patients. In a recent review of renal complications in 
Fabry disease in children the importance of kidney biopsies in the evaluation of ERT 
is highlighted (198) 
The small number of patients limited the statistical analyses. The statistical methods 
were used in a strict regulated way with stepwise evaluation with normality tests, test 
of equality of variances with use of corresponding values and methods. Correlation 
statistics between a semiquantitative and quantitative variable has limitations as the 
p-values often not will be significant. In our case where the p-values are highly 
significant, we believe that the statistics are adequate.  
 
5.1.2.2. Norwegian Kidney Biopsy Registry 
The Norwegian Kidney Biopsy Registry was founded in 1988 and is currently 
probably the biggest active kidney biopsy registry in the world with more than 11000 
biopsies. The registry is basically a quality registry designed for epidemiological 
research, and our study is the first study of biopsy safety and procedure related 
complications in Norway.  A major strength of our safety study (Paper IV) is that it is 
based on high numbers of both pediatric and adult cases over a long period of time. 
The previous publications with comparable numbers are based on review of different 
mainly small single centre studies (139, 140). An overview over studies during the 
last 20 years that were not included in the review-articles from Parrish and Korbet are 
shown in Table III in the introduction of this thesis. Many authors have reported non 
symptomatic hematoma and gross hematuria together with serious complications 
such as the need of blood transfusions, catheter based embolization and surgery when 
discussing major versus minor complications (139, 140, 155). The inclusion of 
different kinds of hospitals in our study; comprising university hospitals with many 
biopsies and small local hospitals performing very few biopsies, gives a nationwide 
perspective with relative homogenous clinical biopsy practice different from the 
majority of previous litererature based on data from larger single centres.  
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The validity and sensitivity of the reporting system in the Norwegian Kidney Biopsy 
Registry may be characterized as high. Only patients that consented to inclusion were 
included. All nephrologists and renal patholologists are asked to admit all available 
cases, and the inclusion rate in general is high. Due to Norwegian privacy legislation 
and no other national way to register the native kidney biopsies in Norway, it is not 
possible to find out exactly how many patients did not sign informed consent or were 
not reported to the Norwegian Kidney Biopsy Registry by the responsible doctor. 
Concerning the sensitivity of the report of complication, cases were excluded when 
the report form was incomplete. Based on the consistency of reporting quality data 
among Norwegian nephrologists we believe it is reasonable to anticipate that if a 
major complication would have been present, the responsible doctor would likely 
have reported such information. The individuals in the study were already ‘pre-
screened’ (general contraindications to kidney biopsies are well known among 
nephrologists), giving a study of safety in patients for whom the risk of biopsy was 
found lower than the potential benefit. There are no absolute exclusion criteria in 
terms of age or eGFR. 
We believe that registered clinical and histopathological data from the Norwegian 
Kidney Biopsy Registry are representative of the entire population as nearly all 
biopsies performed in Norway are included in the Norwegian Kidney Biopsy 
Registry, and the health system in Norway is public and available for free for all 
inhabitants. There is no information in the reports about race, ethnicity and 
socioeconomic status. For the time period 1988-2010 the mean yearly proportion of 
Caucasians was 97 % in the Norwegian population (199). There has been an increase 
of biopsies in general in elderly people in line with general improved health and care 
for elderly. Generally, indications for biopsies are guided by potential benefit. 5.9 % 
of the biopsies in the study period were rebiopsies due to 5.6 % of the patients having 
more than one biopsy performed during the study period. As this percentage is low, 
we believe nclusion of the same individuals more than once has not an important 
influence on the data. 
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Currently there is a debate in the healthcare system if ultrasound guided percutaneous 
renal biopsy should be conducted in a day care setting for low risk patients. This 
organisational change is based on the fact that great majority of complications occur 
within the first 12 hours post biopsy(149). We have not analysed the time span from 
procedure to a complication or day care activity in our study as this information was 
not available in the Norwegian Kidney Biopsy Registry in the time period studied. 
Potential reporting bias and the lack of detailed information about other potential 
complications not pre-specified in the registry report form are limitations in our 
study.  
In the analyses of risk factors for having major complications, we used logistic 
regression analyses. These analyses can be adjusted for possible confoundes and give 
a measure of relative risk associated with the given risk factors. The importance of 
adjusted analyses was clearly demonstrated as only two variables were significant 
after adjustments, low eGFR and small centre size. This means that the apparent risk 
in subjects with high blood pressure or older age (significant in the unadjusted 
analyses) could be accounted for by low eGFR. This does of course not mean that 
blood pressure is irrelevant, but when adequately taken into account at the time of the 
procedure, the blood pressure seems to be less important than might have been 
expected, and does not seem to be a significant risk factor. As the major outcome in 
the study was relatively rare, it is important to keep the number of adjustment factors 
as low as possible and we therefore chose to only adjust for categories of age and 
GFR
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5.2. Discussion of the findings 
5.2.1. Renal evaluation in young Fabry disease patients 
5.2.1.2. Glomerular fitration rate in pediatric Fabry disease 
ely used original Schwartz formula (91, 92) 
overestimated measured GFR substantially by 50.6 ml/min/1.73 m2 with a very low 
accuracy of only 4 % of the values within ± 10 % of the value achieved with 
measured GFR. The same tendency was found in the the comparison of eGFR and 
mGFR measurements in the preceeding Study II. The original Schwartz formula is 
the GFR-equation that for many years has been used in the international Fabry 
registries, Fabry Outcome Survey and Fabry Registry, registries that have important 
world wide impact on prognosis estimates and treatment decisions. The use of this 
formula has made authors report high occurrence of hyperfiltration in Fabry disease 
both in data from the registries as well as from clinical studies (33, 200). The new 
abbreviated Schwartz formula published in 2009 (99) showed the best performances 
of the tested equations in our study with a mean GFR overestimation of 5.3 
ml/min/1.73m2 and 79 % of the eGFR calculated within ± 20 % of measured GFR 
and 49 % within ± 10 %. The Counahan-Barratt formula (90) was only slightly 
inferior to the new abbreviated Schwartz formula, due to a minor difference between 
the quotients in the two formulas. Our findings of the very low accuracy of the 
original Schwartz-formula in children with Fabry disease have contributed to a 
change to the more accurate new abbreviated Schwartz formula in the international 
Fabry registries as well as in clinical trials in pediatric Fabry disease (34, 198, 201, 
202). 
Less than half of the estimated GFR calculations by the new abbreviated Schwartz 
equation were within ± 10 % of the measured GFR in our cohort with normal mGFR. 
It is well known that serum creatinine and all creatinine based GFR equations are 
hampered by inaccuracy in the “creatinine-blind window”. This fact and our results 
show that the use of measured GFR should be part of the routine assessment of the 
The main finding of Study I is that the wid
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kidney function in Fabry children and young adults, since this method is more 
accurate and reduces the risk of missing the diagnosis of early decline of GFR. This is 
especially clinically important when it comes to decisions of initiation of ERT; 
several studies have shown that the effect on nephropathy is attenuated when ERT is 
delayed until the patients reaches CKD stage III (GFR < 60 ml/min/1.73 m2) (34).  
The slightly higher mGFR values found in the Dutch group (not statistically different 
from the Norwegian cohort) could be due to a true difference in GFR in this relatively 
small group (11 patients) of slightly older children (compared to the UK group) and 
mostly female (9 of 11) patients (with corresponding slightly lower creatinine values; 
Table 1, Paper I). In fact, Vedder et al. (61) demonstrated in the Dutch Fabry cohort 
that glomerular hyperfiltration was more frequent in the female group compared to 
male patients; as many as 78 % of female patients had hyperfiltration defined in that 
study as GFR > 125 ml/min. The same Iothalamate-method was used in the Dutch 
cohort in our study and the quality of the method is documented by Apperloo et al. 
(167). Secondly, a systematic bias of Iothalamate clearance is conceivable since 
Iothalamate is subject to minor tubular secretion (203). More important, our finding 
of similar median values for bias for the different equations in the three patients 
groups in spite of the different methods used argues against a systematic bias in our 
study. 
Patient 3 had a great discrepancy between the first mGFR and eGFR, whereas the 
second and the third pair of measurements corresponded pretty well. Two reasons for 
these discrepancies are possible: An analytical random error probably explains the 
difference seen at the first pair of measurements. This patient had serious Fabry 
related akroparestesias, and after introduction of ERT quality of life improved 
substantially. As a consequence, a potential increase of muscle mass due to more 
physical activity may explain better correspondence between GFR methods (higher 
and more correct eGFR) at the second and third GFR timepoint. It has been shown by 
others that body composition (lean patients) may lead to overestimation by eGFR 
(177). This case also illustrates the importance of using exact GFR methods in the 
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evaluation of GFR in Fabry disease patients, especially male patients tend to have 
lower BMI. 
Importantly, a major conclusion in our studies is that probably all GFR-methods (and 
especially the estimated methods), as well as the identification of increasing albumin 
excretion, are “late methods” compared with renal biopsy in the diagnosis of early 
CKD-progression in Fabry disease. Therefore, we think that the use of the best 
available GFR method i.e. mGFR at defined intervals is mandatory in addition to a 
kidney biopsy in the routine monitoring of early Fabry nephropathy when ERT is 
considered. 
 
5.2.1.2. Renal biopsies and effect of enzyme replacement therapy 
Study II was the first kidney biopsy study including male Fabry disease children with 
minimal albuminuria (2, 34), and showed substantial GL3-accumulation in multiple 
celltypes as well as podocyte effacement in all patients. The finding of prominent 
glomerular and vascular morphologic changes in children with Fabry disease long 
before decrease in GFR and development of albuminuria/proteinuria has added 
impotant information to the litterature. Further studies in young Fabry disease 
patients have shown significant correlation between GL3-accumulation and patient 
age and suggest that the cellular damage progresses with increasing age (64). Our 
patient cohort is young and consists of patients with low total disease burden, 
essentially before organ dysfunction is manifest, in a phase where valid biomarkers of 
disease progression currently are unavailable. As a consequence, this cohort 
represents patients with early disease where enzyme replacement therapy (ERT) may 
have a potential for preventing progressive kidney disease.  
Study III is the first systematic re-biopsy study after long-term ERT in children. It is 
also the first report of almost complete clearance of podocyte deposits in a young boy 
after 5 years ERT with agalsidase beta 1.0 mg/kg/ every other week (Figure 3, Paper 
III). Previous studies have demonstrated the capacity of agalsidase beta to reduce 
GL3-inclusions in podocytes (44, 48, 49). Our study is the first time re-biopsies after 
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long term ERT with agalsidase alfa have been studied in a cohort. Our demonstration 
of a cumulative dose effect of the available drugs, irrespective of drug preparation is 
new, and indicates that kidney re-biopsies after 5 years of ERT may be relevant to 
evaluate disease progression and treatment effect as well as allowing for dose 
adjustments if failure of cellular clearance or progressive disease is found. 
Deterioration of GFR was shown in the only available head-to-head comparison of 
agalsidase beta 0.2 mg/kg/eow and agalsidase alfa 0.2 mg/kg/eow over 24 months in 
21 patients with mostly CKD stage I (55) . No kidney biopsies were performed in that 
study. Further studies are needed to clarify the issue; of dose-dependent morphologic 
beneficial effects, and also whether disease duration (patient age) or burden of total 
disease influence the efficacy of drug- induced cellular clearance of GL3-deposits.  
To our knowledge, Paper III is the first demonstration that partial GL3-clearance of 
podocytes is achieveable with standard or double dose agalsidase alfa (0.2-0.4 
mg/kg/eow), as shown in patient 4 (slight clearance) and 5 (substantial clearance) 
(Table 5, Paper III). It is also the first demonstration of total clearance of GL3 in 
mesangial cells. In the randomized controlled trial of agalsidase alfa published in 
2001, 14 patients received agalsidase alfa for six months and twelve of these had a 
renal biopsy. In this trial there was no significant change in total GL3-score in the 
kidneys, but a significant reduction in mesangial widening and vascular endothelium 
GL3-deposits was shown (45). Renal biopsies have not been included in long-term 
trials with agalsidase alfa (193, 204). Schiffmann et al. published a case report after 
treatment with agalsidase alfa for 2.5 years in a 47 years old man who died, and post 
mortem examinations showed lack of GL3 in the vascular endothelium, wheras all 
other kidney cells showed extensive GL3-accumulation (205). In our study we found 
a highly significant correlation between GL3-clearance in the podocytes and 
cumulative alfa-galactosidase dose (Figure 2, Paper III), which may indicate a 
continuous clearance over time. Our findings are in line with previous preclinical 
studies (206) and early phase clinical studies (43) showing a dose-response effect that 
indicates that higher doses are needed to enter the podocytes. In a recent case report 
GL3-deposits remained unchanged in podocytes in Fabry donor kidneys for up to 12 
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years after transplantation despite normal levels of native alfa-Galactosidase in two 
kidney recipients without Fabry disease (207). ERT in patients is different from the 
situation the natural non-Fabry-case and ERT results in high peeks when the infusion 
is given as infusion every two weeks. ERT has a short plasma half-life, but longer 
tissue half-life (42). An important observation in our study was that at least in some 
of the patients treatment with agalsidase alfa in standard or dobbel dose (0.2 
mg/kg/eow or 0.4 mg/kg/eow) was sufficient to achieve some clearance in the 
podocytes. AN important observation in our cohort was that no patients showed 
increasing morphologic damage over the 5 year ERT period, and GFR was stable in 
all patients.    
Moreover, our study supports and expands the dose-dependent effects suggested by 
Lubanda et al. who demonstrated morphologic improvement across many renal cell 
types including podocytes after treatment with agalsidase beta 1.0 mg/kg/eow for 6 
months, and a composite of renal scores was maintained after dose reduction to 0.3 
mg/kg/eow in a subset of proteinuric patients with CKD stage 1 or 2 for a period of 
one year, while progressive cellular damage was observed in some patients after dose 
reduction (50). A more robust decline in urinary GL3 has also been observed when 
higher enzyme dose (agalsidase beta 1.0 mg/kg) was given to patients with 
neutralizing antibodies (56). Recently, an increase of plasma lyso-Gb3 in 17 
clinically stable Fabry disease patients was observed one year after a switch from 
agalsidase beta 1.0 mg/kg/eow to agalsidase alfa 0.2 mg/kg/eow or upon dose 
reduction of agalsidase beta, further indicating a dose-response relationship (58, 62).  
In our study (Paper III) all patients that had substantial clearance of the GL3 in the 
podocytes (three patients treated 5 years with agalsidase beta 1.0 mg/kg/eow and one 
patient treated with agalasidase alfa 0.4 mg/kg/eow for four years followed by 
agalsidase beta 1.0 mg/kg/eow for one year) also showed less podocyte effacement. 
Among the eight patients with mainly unchanged podocyte-GL3 deposits (agalsidase 
0.2 or 0.4 mg/kg/eow) two patients had less podocyte effacement. The partial 
clearance of podocyte GL3 in three of four patients receiving agalsidase beta 1.0 
 75 
mg/kg/eow for the whole or part of the study period is similar to what was shown in 
long-term agalsidase beta treatment by Germain et al. (49). The fourth high-dose (1.0 
mg/kg/eow) patient being the youngest in the study showed almost complete 
clearance of GL3 in the podocytes at the age of 12 years after 5 years of agalsidase 
beta 1.0 mg/kg/eow (Figure 3, Paper III). There is no other case in the literature 
demonstrating high levels of GL3-deposits in the podocytes before start of ERT and 
almost normal looking podocytes after long-term ERT. Whether this conspicuous 
beneficial finding is due to early treatment of a very young patient or specific genetic 
factors or combination of factors, remains to be shown.  
In the Phase III trial in agalsidase beta treated patients (1.0 mg/kg/eow) re-biopsies 
from the kidneys showed that GL3 deposits were cleared after five months (19 
patients) in 100 % of the glomerular capillary endothelial cells and 100 % of the 
mesangial cells  (48).  The placebo-group that switched to active treatment after five 
months also showed a 100 % clearance after 6 months agalsidase beta in the 
glomerular capillary endothelial cells and 90 % of the mesangial cells. The podocytes 
showed a reduction (partial clearance) in 18 % after 11 months of treatment and in 50 
% of the tubular epithelial cells. Another study from Japan with renal biopsies after a 
5 months trial in 13 male Fabry patients on agalsidase beta confirmed the findings 
from the Phase III-trial  (44, 195) showing complete clearance of the endothelial 
cells.   
In our renal biopsy studies (Paper II and III) we used the scoring method published 
by the International Study Group of Fabry Nephropathy (ISGFN) (5). This is the first 
time this model for scoring of potential prognostic histologic markers has been tested 
in a longitudinal study (Paper III). In line with the scoring system of the ISGFN, we 
did not evaluate partial clearance of GL3 in the distal tubuli. On the other hand, 
complete clearance of the distal tubular endothelial cells inclusion was found in two 
of our patients and both were treated with agalsidase beta 1.0 mg/kg/eow for five 
years (patient 1 and 3).  
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As a consequence, it seems that all treatment regimens have the capacity to clear GL3 
deposits in endothelial and mesangial cells, whereas only higher enzyme doses (0.4-
1.0 mg/kg/eow) result in substantial reduction of Gl3-accumulation in the  podocytes. 
The effect on podocytes, a crucial cell in the glomerular filtration barrier, may be a 
more relevant cellular biomarker regarding progression of Fabry nephropathy than 
endothelial or mesangial cells. This concept is further strengthened in our study by 
the very intriguing observation of a clear structural - functional relationship; we 
found concomitant reduction of ACR and podocyte GL3-clearance in the patients 
treated with the highest enzyme dose (Figure 4, Paper III). The clear dose-dependent 
effect on clearance of GL3-deposits from podocytes may indicate that the licensed 
doses of the two available drugs (agalsidase alfa 0.2 mg/kg/eow and agalsidase beta 
1.0 mg/kg/eow) are not clinically equipotent, at least not when it comes to renal 
effects, and supports previous experimental (51, 52) and clinical (55) observations of 
a similar mg-to-mg potency. Our findings have to be confirmed by others in a larger 
patient cohort before any firm conclusions can be drawn, and probably by more 
sophisticated morphometric methods describing podocyte size and fractional volume 
of deposits in line with the studies reported by Najafian et al. (64).  On the other 
hand, if clear morphologic deterioration is found after 5 years, we think enzyme dose 
increase is appropriate in most early case patients. Individualizing of dosing regimens 
with the possibility of either increase or decrease of dose may be a new and relevant 
treatment strategy if podocyte damage proves to be a relevant biomarker of 
progressive disease, and we suggest that a routine repeat kidney biopsy after about 5 
years should be implemented in the surveillance program for young Fabry disease 
patients with likely treatable nephropathy.  
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5.2.2. Safety aspects of percutaneous kidney biopsies 
 
In Studies II-III there were no cases with severe complication after renal biopsy. 
Due to a general fear and resistance to perform kidney biopsies especially in 
children in many centres, no previous biopsy data have been published in Fabry 
children on ERT (208). To explore the risk of complications after kidney biopsies in a 
large patient cohort we decided to perform a study based on data from 9288 biopsies 
registered in the Norwegian Kidney Biopsy Registry during over more than twenty 
years. The main finding in Paper IV is that a kidney biopsy can be regarded as a safe 
procedure in all ages when modern techniques and guidelines are used. We found that 
the low rate of blood transfusion (0.85 %) was even lower in children (0.14 %) than 
in adults (0.85 %) (p=0.03) and surgical intervention including catheterbased 
embolization was on similar low levels in both children (0.14 %) and adults (0.19 
%)(Table 2, Paper IV). A major complication was seen in only two children. 
Moreover, we found lower complication rates han reported in the two main reviews 
in the literature: In Parrish’s report from 1991 of more than 10 000 kidney biopsies 
performed since the 1950s a rate of interventional surgery of 0.29 % was found (139). 
The mortality rate in Parrish’s study was 0.12 %, whereas in our study no deaths were 
reported. Excluding the numbers from Parrish’s study Korbet reported in 2002 a rate 
of blood transfusions of 1.24 %, rate of surgery of 0.23 %, and a mortality rate of 
0.03 % in about 7500 biopsies (140). In the additional studies we reviewed; a total of 
about 9500 biopsies performed the last 20 years, a higher rate of blood transfusions 
(1.22 %), rate of intervention (0.32 %) and mortality rate (0.02 %) was found (Table 
VI, Introduction).  
In our study gross hematuria appeared in 1.7 % of the children and 1.95 % of the 
adults and should not be considered a serious complication unless bleeding is of a 
magnitude causing a significant decline in haemoglobin concentration. The great 
majority of the patients (97.9 %) had neither macroscopic hematuria, nor blood 
transfusion or surgery/embolization in line with other studies (139, 140, 148, 150). 
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Asymptomatic minor perirenal hematoma is not a reliable predictor of a serious 
adverse outcome and should be regarded an epiphenomenon due to the high 
incidence (60-90 %) seen in several prospective studies that include examination with 
ultrasonography or computertomography (140-142, 158). Hematomas are reported to 
be symptomatic in only 1-2 % (146, 151, 158). The higher number of hematomas in 
children in our study is probably due to the lack of definition of the complication 
“hematoma” in the Norwegian Kidney Biopsy Registry and a difference in the 
interpretation of hematoma as complication among the pediatricians compared with 
the nephrologists being responsible for the adult patients.  
The higher relative risk for major complicatons in patients with ower eGFR (Table 4, 
Paper IV) may be related to the general increased bleeding tendency seen in kidney 
failure patients (209) and has been demonstrated by others (144, 149, 210, 211). The 
increased bleeding tendency is probably also the reason for the doubled risk in acute 
renal failure patients in the unadjusted analysis. To minimize the biopsy risk, clinical 
routines to avoid inappropriate use of anticoagulant medication one week prior to as 
well as after the biopsy procedure is important especially when eGFR is reduced. 
 There was a lower relative risk of major complications in the more experienced and 
active centres e.g. university hospitals performing more than 30 biopsies per year 
supporting the view that modern kidney biopsy procedures are safe in experienced 
hands (140). The overall low complication rate also in the smaller centres indicates 
that the routines are adequate also in our smaller centres. Greater variability among 
different centres has recently been demonstrated in other countries (155, 212). 
Morphologic biomarkers assessed by kidney biopsies are important in the diagnosis 
and follow-up of kidney disease in general and is an important prognostic and 
therapeutic guide in many common as well as rare diseases (5, 131-133). There is an  
increased focus on the need of high quality clinical trials in children from the Food 
and Drug Administration and European Medical Association. These important 
changes have implications for the need of scientifically well-founded decicions in the 
treatment of children, including for instance the indication for renal biopsies in 
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children when appropriate (69). Skepticism towards performing a renal biopsy in 
clinical care and clinical trials is often due to the fear of complications especially in 
children, and complications are defined in many papers in a way that includes events 
of minor clinical relevance. Most of these studies are single centre studies in the early 
phase of modern kidney biopsy techniques. Safety data from our large nation-wide 
study do not support an attitude of reluctance to do kidney biopsies to provide 
essential morphologic markers of disease progression or therapeutic adequacy, 
neither in adults nor in children.   
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6. Conclusions  
Estimated GFR should be used with caution and measured GFR should be preferred 
in children with Fabry disease. When estimated GFR is used the new abbreviated 
Schwartz formula should be preferred. 
Renal biopsy gives valuable information about early renal disease before clinical 
signs are visible, and re-biopsies after five years may characterize beneficial effect of 
ERT in patients with normal and stable kidney function. Similar effects on reduction 
of glycosphingolipids (GL3) were found in endothelial and mesangial cells after five 
years of agalsidase alfa 0.2 mg/kg/eow and agalsidase beta 1.0 mg/kg/eow. The 
clearance of GL3-deposits in the podocytes showed dose-dependent effect and 
correlated with cumulative doses of agalsidase. Our findings indicate that agalsidase 
alfa and agalsidase beta are not equivalent in their respective licenced doses. A 
functional-structural relationship was demonstrate by correlation between GL3-
elimination in the podocytes and change in microalbuminuria. 
Renal biopsy is a safe procedure in children and adults when modern guidelines are 
followed. Serious complications were seen in less than 1 % and lower GFR and 
smaller centre-size are risk factors for major complications. 
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7. Future perspectives 
Estimated GFR has important limitations and should be replaced by measured GFR 
in the follow up of young Fabry patients. Iohexol as a non-radioactive substance is a 
good alternative for evaluation of measured GFR and has become a commonly used 
standard tool in many clinical trials. Further studies are needed and are currently 
underway to evaluate single-/few-point methodology as well as finger-prick methods 
in children. 
Renal biopsies are important in the evaluation of treatment of kidney diseases, 
especially in diseases where changes in GFR, albuminuria or other clinical 
biomarkers are inconclusive or do not seem sufficiently sensitive, which is the fact in 
the orphan disease Fabry disease. Based on the present data, kidney biopsies should 
be regarded safe when modern guidelines are followed, and the threshold for 
performing the procedure in the evaluation of treatment effect should be lower in 
many centres. Our findings in kidney biopsies from Fabry disease patients need to be 
confirmed in larger patient cohorts. Secondly, a major issue would be further 
methodologic developments in the characterization of the glycosphingolipid deposits 
in the podocytes and other kidney cell types, and more robust data on structural – 
functional relationships. Thirdly, since no firm evidence up to now has shown that 
progressive kidney disease can be avoided in the long run, we also think that longer 
follow-up of patients with repeat kidney biopsies e.g. after 10 years would provide 
important information regarding the sustainability of the beneficial 5 years data in 
patients with early nepropathy. In this context, it would also be of paramount interest 
to test the effect of dose-adjustments in patients that either remain stable (dose 
reduction?) or show signs of disease progression (dose increase?), and whether the 
morphologic responses in young or older patients behave similar. When it comes to 
ERT and drug doses, it is unlikely that a complex metabolic disease like Fabry 
disease, with highly variable phenotypes, will remain a “one-size-fits-all” disease 
which has been the prevailing treatment philosophy up to now. Fourthly, there is a 
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great need to compare the morphologic cellular changes in the kidney with new and 
older non-invasive biochemical markers. Fifthly, the issue of equipotency of the 
licensed drugs has to be further explored. If our findings of a mg-to-mg similarity 
regarding clinical efficacy in early nephropathy hold true, and if further studies 
confirm that a lower dose will be sufficient in many patients, these observations will 
have substantial beneficial societal consequences for the cost of treatment of Fabry 
disease.  
The newly introduced need of pediatric investigation plans for all new drugs that also 
can be used in children, illustrates the great importance of good study design with 
adequate methods including renal biopsies as well as gold standard measured GFR 
when needed. 
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